

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Characterizing clinical, epidemiological, and etiological aspects in relation to global disease burden assessment of leptospirosis in Sri Lanka: Study Protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-027850
Article Type:	Protocol
Date Submitted by the Author:	20-Nov-2018
Complete List of Authors:	Agampodi, Suneth; Rajarata University, Department of Community Medicine Warnasekara, Janith; Rajarata University of Sri Lanka Faculty of Medicine and Allied Sciences, Department of Community Medicine Jayasundara, Dinesha; Rajarata University of Sri Lanka Faculty of Medicine and Allied Sciences, Department of Microbiology Senawirathna, Indika; Rajarata University of Sri Lanka Faculty of Medicine and Allied Sciences, Department of Biochemistry Gamage, Chandika; Faculty of Medicine. University of Peradeniya, Department of Microbiology Kularatne, Senanayake; Peradeniya University, Sri Lanka, Medicine Siribaddana, Sisira; Rajarata University of Sri Lanka Faculty of Medicine and Allied Sciences, Department of Medicine Maththias, Michael; Yale University School of Medicine Vinetz, Joseph; Yale University School of Medicine
Keywords:	Leptospirosis, Sri Lanka, Leptospira, Isolates, Whole genome sequencing, Clinical disease

SCHOLARONE™
Manuscripts

1 **1 Characterizing clinical, epidemiological, and etiological aspects in relation to global disease**
2 **2 burden assessment of leptospirosis in Sri Lanka: Study Protocol**

3
4
5
6
7 4 Agampodi SB^{1*}, Warnasekara YPJN¹, Jayasundara JMDD², Senavirathna RMISK³, Gamage CD⁴,
8 5 Kularatna SAM⁵, Siribaddana SH⁶, Maththias M⁷, Vinetz JV⁷
9

10
11
12 7 ¹Department of Community Medicine, Faculty of Medicine and Allied Sciences, Rajarata
13 8 University of Sri Lanka

14
15 9 ²Department of Microbiology, Faculty of Medicine and Allied Sciences, Rajarata University of
16 10 Sri Lanka

17
18 11 ³Department of Biochemistry, Faculty of Medicine and Allied Sciences, Rajarata University of Sri
19 12 Lanka

20
21 13 ⁴Department of Microbiology, Faculty of Medicine, University of Peradeniya

22
23 14 ⁵ Department of Medicine, Faculty of Medicine, University of Peradeniya

24
25 15 ⁶Department of Medicine, Faculty of Medicine and Allied Sciences, Rajarata University of Sri
26 16 Lanka

27
28 17 ⁷ Yale School of Medicine, Section of Infectious Diseases, Department of Internal Medicine
29 18 New Haven, CT 06520

30
31
32 19
33 20 ASB: sunethagampodi@yahoo.com,

34 21 WYPJN: jwarnasekara@yahoo.com

35 22 JJMDD: dineshajayasundara@yahoo.com

36 23 SRMISK: irathnabahu@gmail.com

37 24 GCD: chandika@pdn.ac.lk

38 25 KSAM: samkul@sltnet.lk

39 26 SSH: sisira.siribaddana@gmail.com

40 27 MM: mikematthias34@icloud.com

41 28 VJV: joseph.vinetz@yale.edu

42
43
44
45
46 29
47 30 *Corresponding author

48
49
50
51
52
53 31

1 **Abstract**

2 **Introduction**

3 Sri Lanka has one of the highest incidence of leptospirosis worldwide. We hypothesized
4 that different geographical locations and patient context will have a distinct molecular
5 epidemiology of leptospirosis, based on; microgeographic characteristics related to regionally-
6 specific *Leptospira* predominance. Our objective is to characterize clinical, epidemiological, and
7 molecular aspects of leptospirosis in Sri Lanka to understand the disease progression, risk factors
8 and also to have isolates of *Leptospira* from well characterized population to enhance the
9 knowledge on molecular epidemiology of leptospirosis in Sri Lanka.

11 **Methods and Analysis**

12 We designed a multi-center study in Sri Lanka to recruit undifferentiated febrile patients
13 and to follow them up during hospital stay. Patients will be recruited by visiting out patient
14 department and all medical wards. Two main sites (Anuradhapura and Peradeniya) and several
15 additional sites (Awissawella, Ratnapura and Polonnaruwa) will be selected for this study. Blood
16 and urine will be collected from patients on the day of admission to the ward or presentation to the
17 outpatient department. Bedside inoculation of 2 and 4 drops of venous blood will be done into
18 EMJH semisolid media with added antibiotics. Disease confirmation will be done using a
19 regionally optimized MAT (microscopic agglutination test), culture, and qPCR-evidence of the
20 presence of *Leptospira* in blood. For newly isolated *Leptospira*, whole genome sequencing will be
21 done for all isolates. Multi Locus Sequence Typing (MLST) will be used for the genotyping of the
22 new isolates. Sri Lankan isolates will be identified using three published MLST schemes for
23 *Leptospira*.

25 **Ethics and Dissemination**

1 Ethical clearance for the study was obtained from Ethics Review Committees of Rajarata
2 University of Sri Lanka and University of Peradeniya. All data generated through this project will
3 be available for researchers and policy makers on a reasonable request.

5 **Strengths and limitations of this study**

- 6 • This study will be the largest multi-centered prospective study on leptospirosis in Sri
7 Lanka
- 8 • This study will provide robust data on clinical disease progression and predictors of
9 clinical disease, which will be helpful in clinical management of leptospirosis.
- 10 • Culture isolation of *Leptospira* is not carried out for 30 years in Sri Lanka at the time of
11 writing of this protocol and this study will fill that research gap.
- 12 • While having one of the highest incidence, Sri Lankan *Leptospira* isolates has not been
13 undergone whole genome sequencing. This study will enrich the global databases on
14 *Leptospira* genome.

1 Article Summary

- 2 • A prospective recruitment of undifferentiated febrile patients over 3 years
- 3 • Diagnosis of leptospirosis using MAT, qPCR and rapid diagnostic tests
- 4 • Building disease progression models to predict adverse outcomes
- 5 • Culture isolation and typing of *Leptospira spp* to understand the infecting serovar diversity.
- 6 • Whole genome sequencing to expand the knowledge on *Leptospira* genome

For peer review only

1 Introduction

2 Leptospirosis is a globally widespread, neglected and emerging zoonotic disease[1] with
3 estimated 1.03 million cases and 58,900 annual deaths attribute to the disease.[2] An average of
4 2.9 million daily adjusted life years (DALYs) are estimated to be lost every year due to
5 leptospirosis.[3] Emerging leptospirosis mostly affects vulnerable communities living in resource
6 poor settings. Often, the disease is either not suspected or is under or misdiagnosed due to the
7 need for laboratory resources to confirm leptospirosis; typically, such resources are neither
8 accessible nor affordable. From the clinical perspective, better understanding of clinical disease
9 associated with diverse *Leptospira* species is required and better diagnostics are needed to prevent
10 severe complications and death. From the public health perspective, the lack of reliable and
11 efficient diagnostics tests makes assessing the burden of disease--whether regionally or globally--
12 difficult.

13 Sri Lanka has emerged as a country with high incidence of leptospirosis since 2007[4] and in
14 2008, the total number of clinically suspected cases reported to the surveillance system was 7,406
15 with 204 deaths.[5] In 2009, 4980 cases and 145 deaths were reported[6] and the outbreak
16 persisted until 2013 with more than 4000 reported cases each year.[7] The probable case incidence
17 during this time period was more than 20 per 100,000 population, indicating that Sri Lanka has
18 one of the highest reported incidence of leptospirosis worldwide.[8] Our extensive work on 2008
19 outbreak suggested that clinical diagnosis of leptospirosis is highly inaccurate and we could be
20 missing as much as 40% of the leptospirosis patients in hospitals.[9] However, all Sri Lankan
21 studies including our previous study have the same drawback, as observed in most of the
22 published reports in global literature: hospital admission bias, where large number of patients with
23 leptospirosis might have treated as out-patients, which severely underestimate the actual disease
24 burden. Precise disease burden estimates needs seroprevalence studies coupled with population
25 based incidence studies.

1 Our studies on 2011 outbreak of leptospirosis in Anuradhapura showed that the molecular
2 epidemiology, disease transmission and the clinical manifestations of this outbreak were different
3 from what we observed in Central Province (wet zone) in 2008.[10] One of the main concern
4 about these marked variations in *Leptospira* strain and the clinical disease is whether this is due to
5 microgeographical variations, environmental conditions or reservoir mammal infection. It has
6 been shown for other disease like malaria[11, 12] and schistosomiasis[13-15] that
7 microgeography may have a major influence on disease epidemiology. Geochemistry is well
8 described as a major contributory factor in human health.[16] Despite the extensive literature
9 available on leptospirosis, studies on the microgeographic variation of *Leptospira* is scarce.

10 The systematic review done on Sri Lankan isolates showed that more than 40 strains from
11 20 serovars of *Leptospira* have been reported from Sri Lanka.[17] Our previous studies on 2008
12 and 2011 outbreaks of leptospirosis in Sri Lanka expanded the knowledge of circulating
13 *Leptospira* and was consistent with a diversity of *Leptospira* infection in Sri Lanka. We showed
14 that 2008 outbreak was predominantly with *L. interrogans*, compared to post flood outbreak in
15 2011, in which *L.krischneri* was the predominant species. However, the molecular epidemiology
16 of *Leptospira* species in endemic setting is still unknown. In addition to the STNPCR method, we,
17 for the first time showed that previously published MLST schemes could be used with
18 modifications for direct patients samples to study the genetic diversity of infecting leptospiral
19 species in resource-poor settings, where culture and isolation facilities are minimal.[18]

20 One of the most important conclusions we draw from our published work is that qPCR is
21 promising as a clinical diagnostic tool in the diagnosis of leptospirosis during the acute phase with
22 a wider window of positivity than previously noted.[19] The editorial by Katz accompanying this
23 paper[20] endorsed the qPCR approach but also emphasized the need for a prospective evaluation
24 of this method. However, most countries with high leptospirosis burden still find it prohibitively
25 expensive in terms of cost and logistics to have molecular based methods for rapid diagnosis.

1 Disease burden assessment, public health interventions, and clinical management of
2 leptospirosis are challenges due to lack of diagnostic facilities. Any population-based attempt to
3 estimate the disease burden is often challenged by unavailability of diagnostic tests or poor
4 performance of available diagnostic tests. Development of diagnostic tests; global and country
5 specific, requires knowledge on circulating serovars. Further, well-characterized samples are
6 required with species and subspecies level identification of infecting *Leptospira* backed by culture
7 isolation. In Sri Lanka, culture isolation of *Leptospira* has not been reported since 1970s. Even
8 though we showed the microgeographical changes of leptospirosis in 2014[10], no prospective
9 studies have been conducted in leptospirosis literature to primarily identify the disease diversity
10 with specific research design. We hypothesized that different study site and patient context—
11 inpatient vs. outpatient—will have a distinct molecular epidemiology of leptospirosis, based on;
12 Microgeographic characteristics related to regionally-specific *Leptospira* predominance, clinical
13 characteristics related to pathogenesis/virulence potential of specific *Leptospira* species, strains,
14 serovars and the acquisition of infection related to occupational and activities of daily living,
15 reflecting different environmental exposure contexts. Based on these background analyses and
16 hypothesis, the objectives of the present study included;

17 1. To determine the prevalence of leptospirosis among undifferentiated febrile patients
18 (inpatient and outpatient) in contrasting geographical settings in Sri Lanka,

19 2. To describe the full clinical spectrum of leptospirosis in patients infected with
20 *Leptospira*,

21 3. To determine the predictors of leptospirosis progression using a nested case control
22 approach among febrile patients, both inpatient and ambulatory,

23 4. To determine the *Leptospira* species and type diversity in different microgeographical
24 settings in Sri Lanka,

25 5. To characterize Sri Lankan *Leptospira* using MLST and whole genome sequencing
26 methods and

1 6. To have a well characterized collection of serum, whole blood and urine sample for
2
3
4 2 future development and validation of leptospirosis diagnostics
5
6 3
7
8 4
9
10
11
12

13 5 **Methods and Analysis**

14 6 **Study sites**

15
16 7 This study will have four primary subject enrolment/data collection centers in two main
17
18 8 contrasting sites; Kandy and Anuradhapura. In addition, small component of the study will be
19
20 9 carried out in Sabaragamuwa, Western, North Central and Southern provinces for species
21
22 10 diversity (Figure 1). Kandy and Anuradhapura was selected based on our previous observation of
23
24 11 *Leptospira* diversity in these two settings, supported by historically distant identification of
25
26 12 diverse *Leptospira* in Sri Lanka (1960s)[21], without any more recent work; hence this project
27
28 13 will yield modern information at the molecular and genomically-determined taxonomical levels in
29
30 14 addition to conventional methods of identifying *Leptospira*). The first focus is on Anuradhapura,
31
32 15 located in North Central province of Sri Lanka, in the dry zone of the country. The annual rainfall
33
34 16 is 1,200-1600mm and the mean annual temperature is ~30°C. In Anuradhapura area, paddy
35
36 17 farming is carried out by traditional, full-time farmers and provides the main mode of income.
37
38 18 Cattle, water buffalo, certain rodent species—well known sources of *Leptospira* transmission—
39
40 19 are in and round the paddy fields. Paddy fields are large and well maintained. There are no
41
42 20 wetlands or marshy lands in these areas, except the paddy fields during working seasons. Paddy
43
44 21 field work depends on irrigation systems, so between farming seasons, paddy fields become
45
46 22 completely dry. There are probably other risk factors for acquiring leptospirosis from activities of
47
48 23 daily living in economically poor conditions, for example living in proximity to dogs and rodents
49
50 24 in houses and neighborhoods and shoe-ware is often no more than sandals.

51
52
53 25 The soil structure, water quality/hardness, and ecological systems in Anuradhapura
54
55 26 contrast with those of the wet zone of Sri Lanka. Kandy (another historic site in Sri Lanka/Ceylon,
56
57
58
59
60

1 the cultural capital of the country since ancient times) is situated in the wet zone with more than
2 3000mm rainfall and located in the middle, hilly parts of the country. Paddy farming in this area is
3 based on rainwater and the paddy fields remains wet throughout the years. These are small fields
4 adjacent to wildlife and the soil and ecological structure is different from Anuradhapura.
5 Nonetheless, economic conditions of residents in this region are poor and rural, so that rodent- and
6 dog-transmitted *Leptospira* in the context of activities of daily living is likely common but
7 completely unexplored.

8 The purpose of including additional sites is primarily to identify differences in
9 leptospirosis outbreaks especially during floods and unsuspected outbreaks. Only selected
10 components of the study will be done in those areas if there are outbreaks.

12 Study population

13 Study population will include all undifferentiated fever cases either presented to the
14 outpatient department or admitted to medical wards/ICUs in TH Anuradhapura and TH
15 Peradeniya (main sites) and selected hospitals in Western, Sabaragamuwa and Southern
16 provinces.

18 Inclusion criteria:

- 19 • age ≥ 12 yrs
- 20 • temperature $\geq 38^{\circ}\text{C}$
- 21 • self-reported fever ≥ 2 days

23 Exclusion criteria:

- 24 • Influenza-like illness with runny nose and upper respiratory tract symptoms
- 25 • physician-diagnosed probable or definite meningitis or lower respiratory tract infection
26 (e.g. consolidated lobar pneumonia)

- 1 • traumatic or post-operative fever per physician discretion,
- 2 • fever due to nosocomial infections
- 3 • any patient with confirmed diagnosis as a cause for the fever

5 **Patient recruitment**

6 MBBS graduates awaiting their internship appointment and established registrars will be
7 located in all four centers, and directly supervised on a daily basis. They will screen all febrile
8 patients to identify and perform directed physician exams in outpatient department as well as
9 inpatients admitted to medical wards. Once the diagnostic facilities are established, we will let all
10 clinicians in the selected districts know that these facilities are available. If they are interested we
11 will provide diagnostic facilities including cultures, specifically to look at the species diversity.

13 **Procedure:**

14 All possible undifferentiated fever cases will be interviewed and examined by the onsite
15 pre-intern medical officers and suspected leptospirosis cases (fulfilling inclusion and exclusion
16 criteria) will be referred to the study project. In the OPD, once the OPD medical officers complete
17 the history taking and examination, data collector will collect the data. For inward patients, pre-
18 intern medical officer will screen all fever patients on admission to ward, to select eligible
19 patients. In Anuradhapura, four medical units are there and the study will be carried out in all four
20 medical wards. In Peradeniya, a single medical ward is available. Data collectors will visit all
21 wards and ICUs daily for this purpose. Once the routine ward procedures are completed, data
22 collection will be done. All eligible patients will be given an explanatory statement of the study
23 and written informed consent will be obtained before enrolment. Data collection will be done
24 using a fully structured, interviewer administered questionnaire. An additional clinical data check
25 list will be used to assess the clinical features. Daily follow up will be done for all hospitalized
26 patients to observe the clinical progress of the disease. This will be done by using a clinical

1 checklist. The questionnaires and the checklists will be adopted from previously published time
2
3
4 tested protocol.[22]

5
6 All patients will be given an appointment for follow up after two weeks. We will
7
8 maximize the follow up through reminders, telephone calls, and the transport fee will be paid.
9
10 Two ml of blood and a urine sample will be obtained from the follow up patients.
11
12
13
14

15 **Sample size**

16
17 Assuming that around 70% of patients are infected with same infective *Leptospira* strain in
18
19 specific setting and to detect at least 20% difference of in OPD and hospitalized patients, at least
20
21 62 leptospirosis patients with molecular identification are needed from each site. This calculation
22
23 was done to have a power of 80% with an alpha value of 0.05. Based on our previous studies,
24
25 interpretable sequencing data are available for around 50% of confirmed cases of leptospirosis[23]
26
27 and leptospirosis is accounted for 15% of acute undifferentiated fever[24]. Based on these
28
29 assumptions, the total number of febrile patients that is required from one sample collection site
30
31 for this study is 827. This number of patients is conservatively estimated and feasible to obtain
32
33 within the project period.
34
35
36
37
38
39

40 **Sample collection, procession, and storage procedure**

41
42 Blood and urine will be collected from patients on the day of admission to the ward or
43
44 presentation to the outpatient department. Total of 7ml of blood will be collected and bed side
45
46 inoculation of 2 and 4 drops (100µl-500µl) will be done into two tubes containing 9ml of EMJH
47
48 semisolid media with added antibiotics (5-Fluorouracil and Neomycin). 2.5ml of venous blood
49
50 will be collected to an EDTA tube and the rest into plain tubes for serum separation. For serum
51
52 separation, blood in the plain tubes will be centrifuged at 1300rcf for 10 minutes. All blood and
53
54 serum samples will be stored at -80°C for further analysis. Blood collected into EMJH media for
55
56 culture will be incubated at 30°C incubator.
57
58
59
60

1 Ten to fifteen milliliters of clean catch mid stream urine will be collected into a sterile wide
2 mouth container and processed within 2 hours of collection. In a situation where urine can't be
3 processed during the specified time period, pH of urine will be measured with strips and adjusted
4 to around 7.4 using 1N NaOH. Initially urine will be centrifuged at 3000rpm for five minutes to
5 sediment white cells, epithelial cells and other crystals. Then the supernatant will be separated and
6 centrifuged at 15000 rpm for 10 minutes. The resultant sediment will be taken for PCR studies,
7 labeled and stored at -20°C. [25-27] A follow up blood sample (2ml) will be collected into plain
8 tubes for serology and 10-15ml of urine will be collected for PCR studies after 3 weeks from the
9 onset of fever.

11 **Disease confirmation**

12 Disease confirmation will be done using a regionally optimized MAT (microscopic
13 agglutination test), culture, and qPCR-evidence of the presence of *Leptospira* in serum.

15 ***MAT***

16 For this purpose, first we will use the U.S. Centers for Disease Control (CDC) MAT panel with
17 already-available five local strains obtained from Royal Tropical Institute, Amsterdam (KIT).
18 Once Sri Lankan isolates are available, validation of best panel suitable for Sri Lanka will be
19 determined as part of this study. MAT will be done in two main steps. At the first step, serum
20 samples will be screened at a titre of 1/50 by using CDC recommended panel of 24 strains which
21 includes five local strains. At the next step positive sera of screening step will be subjected to the
22 run out test which uses a serial dilution from 1/50 to 1/3200. MAT evidence for seropositivity will
23 be defined as one or more of the following: seroconversion from negative to positive; 4-fold rise
24 in titer between acute-phase and convalescent-phase (follow-up) samples; or a single titer of ≥ 800 .

26 ***Culture isolation of Leptospira***

EMJH semisolid media will be prepared by adding 2.3g of EMJH base, 1.5g of bacteriological agar and 100mg of sodium pyruvate into 785ml of distilled water and adjusting the pH to 7.4. The media will be autoclaved and once it cooled to around 50°C, 100ml of *Leptospira* enrichment media, and 100ml of foetal bovine serum will be added.[28-31] To suppress the growth of possible contaminants, 5 Fluorouracil and Neomycin will be added in 100µg/ml and 25µg/ml concentrations respectively. Inoculated media with blood will be inspected under dark field microscopy for the presence of motile leptospire initially after 3 weeks and then on monthly basis. When a positive growth is detected, sub cultures will be made into liquid and semisolid media and an aliquot will be fixed with 5% DMSO (Dimethyl Sulfoxide) and stored in -80°C. Isolates will be sub cultured in liquid media 2 weekly and on semi solid media 3 monthly. Serotyping of newly isolated *Leptospira* strains will be done in the Pasteur Institute, France

Quantitative PCR

Diagnosis

For the diagnosis, DNA will be extracted from whole blood, serum and urine using QIAamp DNA Blood Mini Kit (Qiagen, USA) according to the manufacture's instruction. Extracted DNA will be quantified using Invitrogen Qubit 4 Fluorometer. Two previously published protocols will be used for detection of pathogenic *Leptospira* DNA. A quantitative PCR based on SYBR Green chemistry targeting 16s ribosomal RNA and LipL32 genes will be used for the diagnosis (Table 1). [32]

Table 1: Primers for detection of *Leptospira* DNA in clinical samples.

Primer/Probe Sequence	Annealing temperature	Complementary target species
Forward: 5' AAG CAT TAC CGC TTG TGG TG3'	60°C	lipL32 gene. of pathogenic

Reverse: 5'GAA CTC CCA TTT CAG CGA TT3'		Leptospira spp
Forward: 5'TAA AGG CTC ACC AAG GCG AC3'	60 °C	16s gene of pathogenic
Reverse: 5'TTA GCC GGT GCT TTA GGC AG3'		Leptospira spp

Speciation

For the determination of *Leptospira* species in clinical samples, a previously published quantitative PCR protocol based on SYBR Green chemistry (Table 2) will be used. For early identification species in cultures (before sequencing) we will use the same protocol. This will allow identification of *L. interrogans*, *L. borgpetersenii*, *L. kirschneri* and *L. noguchii*.

Table 2. Primer pairs for detection of species.

Primer/Probe Sequence	Annealing temperature	Complementary target species
Forward: 5'CTT GAG CCT GCG CGT TAY 3' Reverse: 5'CCG ATA ATT CCA GCG AAG ATC3'	63°C	secY gene of <i>L. interrogans</i>
Forward: 5'GAT TCG GGT TAC AAT TAG ACC3' Reverse: 5'TTG ATC TAA CCG GAC CAT AGT3'	65°C	ompL1 gene of <i>L. borgpetersenii</i>
Forward: 5' CTG GCT TAA TCA ATG CTT CTG 3' Reverse: 5'CTC TTT CGG TGA TCT GTT CC3'	60°C	secY gene of <i>L. kirschneri</i>
Forward: 5'TCA GGG TGT AAG AAA GGT TC 3' Reverse: 5'CAA AAT TAA AGA AGA AGC AAA GA3'	63°C	secY gene of <i>L. noguchii</i>

Molecular studies

For newly isolated *Leptospira*, whole genome sequencing will be done using two technologies; MinION Nanopore sequencing in the Leptospirosis research lab, Faculty of Medicine and Allied Sciences, Rajarata University of Sri Lanka and Pacbio sequencing at the Institute for Genomic Medicine, University of California, San Diego.

BAS and BAX files contain all information on DNA sequences will be converted to fasta file. Prior to the assembly the quality (coverage) of the raw data will be assessed. Using PacBioEDA software the quality summary of the data will be obtained. CanuPacBio assembly

1 program will be used for genome assembly. The raw data of Bas/Bax files will be converted to
2 Bam files by using the bax2bam software. These bam files of reads will be aligned to our
3 references using Pbalngn software. The software Quiver will be used for the polishing of data.
4 Assembled data will be annotated by Prokka[33] and Roary[34] software and annotations will be
5 inspected and curated using Artemis. The functional annotation will be done using eggNOG and
6 eggNOG MAPPER online tools.[35] Genomes of the Sri Lankan isolates will be compared using
7 MAUVE software. The organism will be roughly identified from the direct raw data using
8 KRAKEN.[36]

9 Multi Locus Sequence Typing (MLST) will be used for the genotyping of the new isolates.
10 Sri Lankan isolates will be identified using three published MLST schemes for *Leptospira*. [37-39]
11 Genetic similarity between isolates will be determined using SPLITSTREE software.

13 **Taxonogenomics, pan-genome and phylogenetic analyses**

14 In order to establish how this strain was related to other *Leptospira*, we will use several
15 genomic analysis. First, 16S rRNA sequences will be used to construct a phylogeny. High
16 sequence identities ($\geq 97\%$) between newly sequenced strain and other
17 recognized *Leptospira* strains will be used preliminarily as suggestive of phylogenetic
18 relationships. Accordingly, 16S rRNA gene sequences of *Leptospira* spp. deposited in GenBank
19 database will be acquired. Multiple sequence alignment based on 16S rRNA will be performed
20 using a ClustalX v1.81. These result will be then used to construct the maximum likelihood tree
21 implementing MEGA v5.05. To evaluate clade support, we will construct a bootstrap analysis
22 with 1,000 replicates. Relationship of each sequenced genome to previously described or novel
23 leptospiral species will be determined by Overall Genetic Relatedness Indices (OGRI). Average
24 Nucleotide Identity (ANI) and the Average Amino Acid Identity (AAI). Both indices will be
25 automatically calculated using two-way BLAST + blastn and blastp. For ANI calculation, default

1 parameters: sequence identity cut-off, 30%; alignment cut-off, 70%; and query length, 1,020 bp
2 will be applied.
3
4

4 **Data management and analysis**

5 Patient interviews and patient health records will be used as data sources. On site data
6 entry will be done in real time for all collected data. EpiInfo database will be prepared using cross
7 checks, field validation and other inbuilt techniques available for data quality improvement.
8 Investigators will frequently visit the hospitals to cross validate collected data. All databases will
9 be kept under password-protected computers. Only the investigators and data entry assistants will
10 have access to the database. Databases will not include the personal identification data and those
11 information in the hardcopies will be kept in separately.

12 Proportions and 5% confidence intervals will be used to describe the confirmed cases,
13 diversity of infecting *Leptospira* and sequelae. Chi-square test for trend will be used to test
14 significant differences of *Leptospira* diversity at different microgeographical and clinical settings.
15 Predictors of leptospirosis and severe disease will be analyzed using a logistic regression model.
16 Model building will be done using a conceptual hierarchy of determinants, which we proposed for
17 leptospirosis earlier. Online database for *Leptospira* MLST will be used for typing analysis.

19 **Patient and Public Involvement**

20 The study was developed using the patients' feedback we received on leptospirosis disease
21 burden, it's impact on their lives, and especially the problems they are facing during the illness.
22 During the previous studies, we specifically looked at patients as well as general public views on
23 leptospirosis disease and prevention, which was used for designing this study. Results of the study
24 will be disseminated in a continues basis for patients. We have already conducted several public
25 awareness as well as health worker education workshops based on our findings.

1 Ethics and dissemination

2 Undifferentiated fever patients eligible for the study will be given an explanatory
3 statement of the study and written informed consent will be obtained before enrolment. Rapid
4 diagnostic kits will be used and the results will be available for treating physicians. qPCR
5 diagnostic facilities will be provided for all patients whenever the urgent tests are requested by
6 treating physicians. All test results will be informed to the patients and the wards. Ethical
7 clearance for the study was obtained from the Ethic Review Committees of Faculty of Medicine
8 and Allied Sciences, Rajarata University of Sri Lanka (ERC/2015/18).

9 All genomic data will be deposited in Gene Bank. Characterized serum samples will be
10 stored in -80C in the Faculty of Medicine and Allied Sciences, Rajarata University of Sri Lanka.
11 Data pertaining to this study will be available for researchers and policy makers on a reasonable
12 request address to the corresponding author. After the completion of work, data will be deposited
13 in a repository.

15 References

- 16 1. WER: **Leptospirosis worldwide, 1999**. *Wkly Epidemiol Rec* 1999, **74**(29):237-242.
- 17 2. Costa F, Hagan JE, Calcagno J, Kane M, Torgerson P, Martinez-Silveira MS, Stein C,
18 Abela-Ridder B, Ko AI: **Global Morbidity and Mortality of Leptospirosis: A**
19 **Systematic Review**. *PLoS Negl Trop Dis* 2015, **9**(9):e0003898.
- 20 3. Taylor AJ, Paris DH, Newton PN: **A Systematic Review of the Mortality from**
21 **Untreated Leptospirosis**. *PLoS Negl Trop Dis* 2015, **9**(6):e0003866.
- 22 4. Agampodi S, Peacock SJ, Thevanesam V: **The potential emergence of leptospirosis**
23 **in Sri Lanka**. *Lancet Infect Dis* 2009, **9**(9):524-526.
- 24 5. Epidemiological Unit: **Selected notifiable diseases reported by Medical Officers of**
25 **Health**. *Weekly Epidemiological Report* 2009, **36**(1):4.
- 26 6. Epidemiological Unit: **Selected notifiable diseases reported by Medical Officers of**
27 **Health**. *Weekly Epidemiological Report* 2010, **37**(1):4.
- 28 7. Warnasekara JN, Agampodi S: **Leptospirosis in Sri Lanka**. *Sri Lankan Journal of*
29 *Infectious Diseases* 2017, **7**(2).
- 30 8. Pappas G, Papadimitriou P, Siozopoulou V, Christou L, Akritidis N: **The globalization**
31 **of leptospirosis: worldwide incidence trends**. *Int J Infect Dis* 2008, **12**(4):351-357.
- 32 9. Agampodi SB, Peacock SJ, Thevanesam V, Nugegoda DB, Smythe L, Thaipadungpanit J,
33 Craig SB, Burns MA, Dohnt M, Boonsilp S *et al*: **Leptospirosis outbreak in Sri Lanka**
34 **in 2008: lessons for assessing the global burden of disease**. *Am J Trop Med Hyg*
35 2011, **85**(3):471-478.

10. Agampodi SB, Dahanayaka NJ, Bandaranayaka AK, Perera M, Priyankara S, Weerawansa P, Matthias MA, Vinetz JM: **Regional differences of leptospirosis in Sri Lanka: observations from a flood-associated outbreak in 2011.** *PLoS Negl Trop Dis* 2014, **8**(1):e2626.
11. Myers WP, Myers AP, Cox-Singh J, Lau HC, Mokuai B, Malley R: **Micro-geographic risk factors for malarial infection.** *Malaria journal* 2009, **8**:27.
12. Schellenberg JA, Newell JN, Snow RW, Mung'ala V, Marsh K, Smith PG, Hayes RJ: **An analysis of the geographical distribution of severe malaria in children in Kilifi District, Kenya.** *Int J Epidemiol* 1998, **27**(2):323-329.
13. Hassan AO, Amoo AOJ, Deji-Agboola AM, Adeleke MA, Muhibi MA, Hassan RO: **Microgeographical patterns of schistosomiasis and anthropometric indices of children in eko-ende south west, nigeria.** *Int J Biol Med Res* 2011, **2**(3):656-660.
14. Kloos H, Gazzinelli A, Van Zuyle P: **Microgeographical patterns of schistosomiasis and water contact behavior; examples from Africa and Brazil.** *Mem Inst Oswaldo Cruz* 1998, **93 Suppl 1**:37-50.
15. Baliraine FN, Afrane YA, Ameny DA, Bonizzoni M, Menge DM, Zhou G, Zhong D, Vardo-Zalik AM, Githeko AK, Yan G: **High prevalence of asymptomatic plasmodium falciparum infections in a highland area of western Kenya: a cohort study.** *J Infect Dis* 2009, **200**(1):66-74.
16. Dissanayake CB, Chandrajith R: **Medical geochemistry of tropical environments.** *Earth-Science Reviews* 1999, **47**(3-4):219-258.
17. Naotunna C, Agampodi SB, Agampodi TC: **Etiological agents causing leptospirosis in Sri Lanka: A review.** *Asian Pac J Trop Med* 2016, **9**(4):390-394.
18. Agampodi SB, Moreno AC, Vinetz JM, Matthias MA: **Utility and limitations of direct multi-locus sequence typing on qPCR-positive blood to determine infecting Leptospira strain.** *Am J Trop Med Hyg* 2013, **88**(1):184-185.
19. Agampodi SB, Miatthias MA, Moreno AC, Vinetz JM: **Utility of Quantitative PCR in Leptospirosis Diagnosis: Association of Level of Leptospiremia and Clinical Manifestations in Sri Lanka.** *Clinical Infectious Disease* 2012, **In Press**.
20. Katz AR: **Quantitative polymerase chain reaction: filling the gap for early leptospirosis diagnosis.** *Clin Infect Dis* 2012, **54**(9):1256-1258.
21. Nityananda K, Harvey T: **Leptospirosis in Ceylon-Epidemiological and Laboratory Studies.** *Ceylon J Med Sci* 1971, **20**(1):5-14.
22. Agampodi SB, Nugegoda DB, Thevanesam V: **Determinants of leptospirosis in Sri Lanka: Study Protocol.** *BMC Infect Dis* 2010, **10**(1):332.
23. Agampodi SB, Matthias MA, Moreno AC, Vinetz JM: **Utility of quantitative polymerase chain reaction in leptospirosis diagnosis: association of level of leptospiremia and clinical manifestations in Sri Lanka.** *Clin Infect Dis* 2012, **54**(9):1249-1255.
24. Reller ME, Bodinayake C, Nagahawatte A, Devasiri V, Kodikara-Arachichi W, Strouse JJ, Flom JE, Dumler JS, Woods CW: **Leptospirosis as frequent cause of acute febrile illness in southern Sri Lanka.** *Emerg Infect Dis* 2011, **17**(9):1678-1684.
25. Lucchesi PM, Arroyo GH, Etcheverria AI, Parma AE, Seijo AC: **Recommendations for the detection of Leptospira in urine by PCR.** *Rev Soc Bras Med Trop* 2004, **37**(2):131-134.
26. Bal AE, Gravekamp C, Hartskeerl RA, De Meza-Brewster J, Korver H, Terpstra WJ: **Detection of leptospire in urine by PCR for early diagnosis of leptospirosis.** *J Clin Microbiol* 1994, **32**(8):1894-1898.
27. Van Eys GJ, Gravekamp C, Gerritsen MJ, Quint W, Cornelissen MT, Schegget JT, Terpstra WJ: **Detection of leptospire in urine by polymerase chain reaction.** *J Clin Microbiol* 1989, **27**(10):2258-2262.

- 1 28. Wuthiekanun V, Amornchai P, Langla S, Oyuchua M, Day NP, Limmathurotsakul D:
2 **Maintenance of leptospira species in leptospira Vanaporn Wuthiekanun agar.** *J*
3 *Clin Microbiol* 2014, **52**(12):4350-4352.
- 4 29. Wuthiekanun V, Amornchai P, Langla S, White NJ, Day NP, Limmathurotsakul D,
5 Peacock SJ: **Antimicrobial Disk Susceptibility Testing of Leptospira spp. Using**
6 **Leptospira Vanaporn Wuthiekanun (LVW) Agar.** *Am J Trop Med Hyg* 2015,
7 **93**(2):241-243.
- 8 30. Wuthiekanun V, White NJ, Amornchai P, Day NP, Limmathurotsakul D: **Quality**
9 **controls for antimicrobial disk diffusion testing on Leptospira Vanaporn**
10 **Wuthiekanun agar.** *Trans R Soc Trop Med Hyg* 2016, **110**(11):673-675.
- 11 31. Picardeau M, Bulach DM, Bouchier C, Zuerner RL, Zidane N, Wilson PJ, Creno S,
12 Kuczek ES, Bommezzadri S, Davis JC *et al*: **Genome sequence of the saprophyte**
13 **Leptospira biflexa provides insights into the evolution of Leptospira and the**
14 **pathogenesis of leptospirosis.** *PLoS ONE* 2008, **3**(2):e1607.
- 15 32. Backstedt BT, Buyuktanir O, Lindow J, Wunder EA, Reis MG, Usmani-Brown S, Ledizet
16 M, Ko A, Pal U: **Efficient Detection of Pathogenic Leptospire Using 16S**
17 **Ribosomal RNA.** *PLOS ONE* 2015, **10**(6):e0128913-e0128913.
- 18 33. Seemann T: **Prokka: rapid prokaryotic genome annotation.** *Bioinformatics* 2014,
19 **30**(14):2068-2069.
- 20 34. Page AJ, Cummins CA, Hunt M, Wong VK, Reuter S, Holden MT, Fookes M, Falush D,
21 Keane JA, Parkhill J: **Roary: rapid large-scale prokaryote pan genome analysis.**
22 *Bioinformatics* 2015, **31**(22):3691-3693.
- 23 35. Huerta-Cepas J, Forslund K, Coelho LP, Szklarczyk D, Jensen LJ, von Mering C, Bork P:
24 **Fast Genome-Wide Functional Annotation through Orthology Assignment by**
25 **eggNOG-Mapper.** *Mol Biol Evol* 2017, **34**(8):2115-2122.
- 26 36. Wood DE, Salzberg SL: **Kraken: ultrafast metagenomic sequence classification**
27 **using exact alignments.** *Genome Biol* 2014, **15**(3):R46.
- 28 37. Varni V, Ruybal P, Lauthier JJ, Tomasini N, Brihuega B, Koval A, Caimi K:
29 **Reassessment of MLST schemes for Leptospira spp. typing worldwide.** *Infect*
30 *Genet Evol* 2014, **22**:216-222.
- 31 38. Ahmed N, Devi SM, Valverde Mde L, Vijayachari P, Machang'u RS, Ellis WA, Hartskeerl
32 RA: **Multilocus sequence typing method for identification and genotypic**
33 **classification of pathogenic Leptospira species.** *Ann Clin Microbiol Antimicrob*
34 *2006*, **5**:28.
- 35 39. Boonsilp S, Thaipadungpanit J, Amornchai P, Wuthiekanun V, Bailey MS, Holden MT,
36 Zhang C, Jiang X, Koizumi N, Taylor K *et al*: **A single multilocus sequence typing**
37 **(MLST) scheme for seven pathogenic Leptospira species.** *PLoS Negl Trop Dis*
38 *2013*, **7**(1):e1954.

41 Author statement

42 Authors' contributions

43 JMV and SBA drafted the initial protocol. YPJNW, JMDDJ and RMISKS are responsible
44 for the detailed design, field/ laboratory work analysis and interpretation of objectives 1-3, 4 and 5

1 respectively. CDG, SAMK and SHS helped in design, field, hospital and laboratory work. MM
2 participated in scientific design and guided all laboratory components. All authors have read and
3 approved the manuscript.

4 **Funding**

5 This project is the Sri Lankan component of a multi country study funded by the NIAID of
6 the National Institutes of Health under award number U19AI115658. Funders had no role in the
7 design, execution, analyses, data interpretation, or decision to submit results.

8 **Conflicts of interests**

9 The authors declare that they have no competing interests.

10 **Word count**

11 3595


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Figure titles**

2 Figure 1: Locations of study sites.

3 Figure was prepared by the first author using Google maps (<https://www.google.com/maps>).

For peer review only



Locations of study sites

BMJ Open

Study protocol: Characterizing the clinical, epidemiological, and etiological aspects of leptospirosis in Sri Lanka

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-027850.R1
Article Type:	Protocol
Date Submitted by the Author:	29-May-2019
Complete List of Authors:	Agampodi, Suneth; Rajarata University, Department of Community Medicine Warnasekara, Janith; Rajarata University of Sri Lanka Faculty of Medicine and Allied Sciences, Department of Community Medicine Jayasundara, Dinesha; Rajarata University of Sri Lanka Faculty of Medicine and Allied Sciences, Department of Microbiology Senawirathna, Indika; Rajarata University of Sri Lanka Faculty of Medicine and Allied Sciences, Biochemistry Gamage, Chandika; University of Peradeniya Faculty of Medicine, Microbiology Kularatne, Senanayake; University of Peradeniya Faculty of Medicine, Medicine Siribaddana, Sisira; Rajarata University of Sri Lanka Faculty of Medicine and Allied Sciences, Department of Medicine Maththias, Michael; Yale University School of Medicine Vinetz, Joseph; Yale University School of Medicine
Primary Subject Heading:	Infectious diseases
Secondary Subject Heading:	Epidemiology, Global health, Public health, Infectious diseases
Keywords:	Leptospirosis, Sri Lanka, Leptospira, Isolates, Whole genome sequencing, Clinical disease

SCHOLARONE™
Manuscripts

1 **1 Study protocol: Characterizing the clinical, epidemiological, and etiological aspects of**
2 **2 leptospirosis in Sri Lanka**

3
4
5
6
7 4 Agampodi SB^{1*}, Warnasekara YPJN¹, Jayasundara JMDD², Senawirathna RMISK³, Gamage
8 CD⁴, Kularatne SAM⁵, Siribaddana SH⁶, Maththias M⁷, Vinetz JV⁷
9

10
11
12 7 ¹ Department of Community Medicine, Faculty of Medicine and Allied Sciences, Rajarata
13 University of Sri Lanka
14

15 9 ² Department of Microbiology, Faculty of Medicine and Allied Sciences, Rajarata University of
16 Sri Lanka
17

18 11 ³ Department of Biochemistry, Faculty of Medicine and Allied Sciences, Rajarata University of
19 Sri Lanka
20

21 13 ⁴ Department of Microbiology, Faculty of Medicine, University of Peradeniya
22

23 14 ⁵ Department of Medicine, Faculty of Medicine, University of Peradeniya
24

25 15 ⁶ Department of Medicine, Faculty of Medicine and Allied Sciences, Rajarata University of Sri
26 Lanka
27

28 17 ⁷ Yale School of Medicine, Section of Infectious Diseases, Department of Internal Medicine
29 New Haven, CT 06520
30

31 19
32 20 ASB: sunethagampodi@yahoo.com,
33

34 21 WYPJN: jwarnasekara@yahoo.com
35

36 22 JJMDD: dineshajayasundara@yahoo.com
37

38 23 SRMISK: irathnabahu@gmail.com
39

40 24 GCD: chandika@pdn.ac.lk
41

42 25 KSAM: samkul@sltnet.lk
43

44 26 SSH: sisira.siribaddana@gmail.com
45

46 27 MM: mikematthias34@icloud.com
47

48 28 VJV: joseph.vinetz@yale.edu
49

50 29

51 30 *Corresponding author.
52

53 31
54
55
56
57
58
59
60

1 ABSTRACT

2 **Introduction:** Sri Lanka has one of the highest incidences of leptospirosis worldwide. We
3 hypothesized that different geographical locations and patient context will have a distinct
4 molecular epidemiology of leptospirosis, based on microgeographic characteristics related to
5 regiona-specific *Leptospira* predominance. Our objective is to characterize the clinical,
6 epidemiological, and molecular aspects of leptospirosis in Sri Lanka to understand disease
7 progression, risk factors, and obtain isolates of *Leptospira* from well-characterized populations to
8 enhance the understanding of molecular epidemiology of leptospirosis in Sri Lanka. **Methods and**
9 **Analysis:** We designed a multi-center prospective study in Sri Lanka to recruit undifferentiated
10 febrile patients and conduct follow-ups during hospital stays. Patients will be recruited from
11 outpatient departments and medical wards. This study will be conducted at two main sites
12 (Anuradhapura and Peradeniya) and several additional sites (Awissawella, Ratnapura and
13 Polonnaruwa). Blood and urine will be collected from patients on the day of admission to the
14 ward or presentation to the outpatient department. Bedside inoculation of 2 and 4 drops of venous
15 blood will be performed with EMJH semisolid media supplemented with antibiotics. Regionally
16 optimized microscopic agglutination test, culture, and qPCR-evidence will be performed to
17 confirm the presence of *Leptospira* in blood, which in turn will confirm the presence of disease.
18 Whole genome sequencing will be carried out for all isolates recovered from patients. Multi locus
19 sequence typing (MLST) will be used for the genotyping of new isolates. Sri Lankan isolates will
20 be identified using three published MLST schemes for *Leptospira*. **Ethics and Dissemination:**
21 Ethical clearance for the study was obtained from Ethics Review Committees of Rajarata
22 University of Sri Lanka and University of Peradeniya. All genomic data generated through this
23 project will be available at GenBank. For the ethics approval, anonymized data will be deposited
24 at the Ethics Review Committee of Faculty of Medicine and Allied Sciences, Rajarata University
25 of Sri Lanka and is available for researchers and policy makers.

26 27 STRENGTHS AND LIMITATIONS OF THIS STUDY

- 1 • This is a multi-center study involving wet and dry zones, low and highlands and high
2 endemic and low endemic areas of the country covering different geographical and climate
3 zones to provide a better understanding of leptospirosis in Sri Lanka.
4 • We will use a prospective study design focusing on culture isolation as a main aim with
5 specific protocols for the particular objective to describe the strain diversity of *Leptospira*
6 *spp.* in Sri Lanka.
7 • Clinical and epidemiological data will be collected as primary data to ensure high quality
8 data using clinically trained health professionals.
9 • Since *Leptospira* are fastidious organisms, the culture yield will be low and linking the
10 clinical disease with isolated *Leptospira* may be partly confounded by the growth
11 potentials of different *Leptospira*.
12 • Since PCR and culture-based methods are typically valid only during the first 7-10 days of
13 the illness and late presentations may lead to reduce sensitivity of these tests, MAT is best
14 interpreted with paired samples, and a lack of convalescent samples will impair the
15 interpretation of MAT results.

1 INTRODUCTION

2 Leptospirosis is a globally widespread, neglected, and emerging zoonotic disease[1] with
3 estimated 1.03 million cases and 58,900 annual deaths attributed to the disease.[2] An average of
4 2.9 million daily adjusted life years (DALYs) are estimated to be lost every year due to
5 leptospirosis.[3] Emerging leptospirosis mostly affects vulnerable communities living in resource-
6 poor settings. Often, the disease is either not suspected or is under or misdiagnosed due to the
7 need for laboratory resources to confirm leptospirosis; typically, such resources are neither
8 accessible nor affordable. From the clinical perspective, a better understanding of the clinical
9 disease associated with diverse *Leptospira* species is required and superior diagnostics are needed
10 to prevent severe complications and death. From the public health perspective, the lack of reliable
11 and efficient diagnostic tests makes assessing the burden of disease—whether regionally or
12 globally—difficult.

13 Sri Lanka has emerged as a country with a high incidence of leptospirosis since 2007[4] and
14 in 2008, the total number of clinically suspected cases reported to the surveillance system was
15 7,406 with 204 deaths.[5] In 2009, 4980 cases and 145 deaths were reported[6], and the outbreak
16 persisted until 2013 with more than 4000 reported cases each year.[7] The probable case incidence
17 during this time period was more than 20 per 100,000 population, indicating that Sri Lanka has
18 one of the highest reported incidences of leptospirosis worldwide.[8] Our extensive work on the
19 2008 outbreak suggested that clinical diagnosis of leptospirosis is highly inaccurate, since as
20 much as 40% of the leptospirosis patients are misdiagnosed in hospitals.[9] However, all Sri
21 Lankan studies, including our previous study, have the same drawback, as observed in most of the
22 published reports in global literature: hospital admission bias, where a large number of patients
23 with leptospirosis may have been treated as outpatients, which leads to a severe underestimate of
24 the actual disease burden. A precise disease burden estimate requires seroprevalence studies
25 coupled with population-based incidence studies.

26 Our studies on the 2011 outbreak of leptospirosis in Anuradhapura showed that the molecular
27 epidemiology, disease transmission, and clinical manifestations of this outbreak were different

1 from those observed in Central Province (wet zone) in 2008.[10] One of the main concerns
2 regarding these marked variations in the *Leptospira* strain and the clinical disease was whether
3 this was due to microgeographical variations, environmental conditions, or reservoir mammal
4 infection. It has been shown for other diseases such as malaria[11, 12] and schistosomiasis[13-
5 15], that microgeography may have a major influence on disease epidemiology. Geochemistry is a
6 well-known and major contributory factor in human health.[16] Despite the extensive literature
7 available on leptospirosis, studies on the microgeographic variation of *Leptospira* are scarce.

8 A systematic review performed on Sri Lankan isolates showed that more than 40 strains
9 from 20 serovars of *Leptospira* have been reported from Sri Lanka.[17] Our previous studies on
10 the 2008 and 2011 outbreaks of leptospirosis in Sri Lanka expanded the knowledge of circulating
11 *Leptospira* and were consistent with a diversity of *Leptospira* infection in Sri Lanka. We showed
12 that in the 2008 outbreak, *L. interrogans* was the predominant species, compared to the post-flood
13 outbreak in 2011, in which *L. kirschneri* was the predominant species. However, the molecular
14 epidemiology of *Leptospira* species in endemic settings remains unknown in Sri Lanka. In
15 addition to the STNPCR method, for the first time, we showed that previously published multi
16 locus sequence typing (MLST) schemes could be used with modifications for direct patients
17 samples to study the genetic diversity of infecting *Leptospira* species in resource-poor settings,
18 where the facilities needed to perform cultures and isolations are minimal.[18]

19 One of the most important conclusions we draw from our published work is that qPCR is
20 promising as a clinical diagnostic tool in the diagnosis of leptospirosis during the acute phase,
21 with a wider window of positivity than previously noted.[19] The editorial by Katz[20] endorsed
22 the qPCR approach but also emphasized the need for a prospective evaluation of this method.
23 However, most countries with high leptospirosis burdens still find it prohibitively expensive to
24 have molecular based methods for rapid diagnosis, in terms of both the costs and logistics.

25 Disease burden assessment, public health interventions, and clinical management of
26 leptospirosis are challenges due to the lack of diagnostic facilities. Any population-based attempt

1 to estimate the disease burden is often limited by the unavailability of diagnostic tests or the poor
2 performance of the available diagnostic tests. The development of diagnostic tests that are both
3 global and country-specific requires knowledge on circulating serovars. Furthermore, well-
4 characterized samples are required with species and subspecies level identification of infecting
5 *Leptospira* backed by culture isolations. In Sri Lanka, a culture isolation of *Leptospira* has not
6 been reported since the 1970s. Even though we showed the microgeographical changes of
7 leptospirosis in 2014,[10] no prospective studies have been conducted in a Sri Lankan cohort to
8 primarily identify the disease diversity with specific research design. We hypothesized that a
9 different study site and patient context—inpatient vs. outpatient—will have a distinct molecular
10 epidemiology of leptospirosis, based on microgeographic characteristics related to region-specific
11 *Leptospira* predominance, clinical characteristics related to pathogenesis/virulence potential of
12 specific *Leptospira* species, strains, serovars, and the acquisition of infection related to
13 occupational and activities of daily living, reflecting different environmental exposure contexts.
14 Based on these background analyses and hypotheses, the objectives of the present study were as
15 follows:

- 16 1. To determine the prevalence of leptospirosis among undifferentiated febrile patients
17 (inpatient and outpatient) in contrasting geographical settings in Sri Lanka.
- 18 2. To describe the full clinical spectrum of leptospirosis in patients infected with
19 *Leptospira*.
- 20 3. To determine the predictors of leptospirosis progression using a nested case control
21 approach among febrile patients, both inpatient and ambulatory.
- 22 4. To determine the *Leptospira* species and type diversity in different geographical settings
23 in Sri Lanka.
- 24 5. To characterize Sri Lankan *Leptospira* using MLST and whole genome sequencing
25 methods.

1 1 6. To have a well-characterized collection of serum, whole blood, and urine samples for
2
3
4 2 the future development and validation of leptospirosis diagnostics.
5
6 3

8 4 **METHODS AND ANALYSIS**

9 5 **Study sites**

11 6 This study will be performed in four primary subject enrolment/data collection centers in
12
13
14 7 two main contrasting sites: Kandy and Anuradhapura. In addition, a small component of the study
15
16 8 will be carried out in Sabaragamuwa, Western, North Central, and Southern provinces for species
17
18 9 diversity (Figure 1). Kandy and Anuradhapura was selected based on our previous observations of
19
20 10 *Leptospira* diversity in these two settings, supported by historically distant identification of
21
22 11 diverse *Leptospira* in Sri Lanka (1960s)[21]. Since no recent studies have been conducted, this
23
24 12 project will yield up-to-date information at the molecular and genomically-determined
25
26 13 taxonomical levels in addition to conventional methods of identifying *Leptospira*. The initial
27
28 14 focus is on Anuradhapura, located in North Central province of Sri Lanka, in the dry zone of the
29
30 15 country. The annual rainfall is 1,200-1,600 mm, with a mean annual temperature of ~30°C. In
31
32 16 Anuradhapura, paddy farming is carried out by traditional, full-time farmers and constitutes the
33
34 17 main mode of income. Cattle, water buffalo, certain rodent species—well-known sources of
35
36 18 *Leptospira* transmission—are found in and around the paddy fields. Paddy fields are large and
37
38 19 well maintained. There are no wetlands or marshy lands in these areas, except the paddy fields
39
40 20 during working seasons. Paddy field work depends on irrigation systems, such that, between
41
42 21 farming seasons, the paddy fields become completely dry. Other risk factors for acquiring
43
44 22 leptospirosis include daily activities involved in living in economically poor conditions, for
45
46 23 example living in proximity to dogs and rodents in houses and neighborhoods and the wearing of
47
48 24 shoes that are often no more than sandals.

55 25 The soil structure, water quality/hardness, and ecological systems in Anuradhapura
56
57 26 contrast with those of the wet zone of Sri Lanka. Kandy (another historic site in Sri Lanka/Ceylon,
58
59 27 the cultural capital of the country since ancient times) is situated in the wet zone, with over 3,000

1 mm of rainfall, and is located in the middle, hilly parts of the country. Paddy farming in this area
2 is based on rainwater and the paddy fields remain wet throughout the year. These are small fields
3 adjacent to wildlife and the soil and ecological structure is different from that in Anuradhapura.
4 Nonetheless, the economic conditions of residents in this region are poor and rural, such that
5 rodent- and dog-transmitted *Leptospira* in the context of activities of daily living is likely
6 common but completely unexplored.

7 The purpose of including additional sites is primarily to identify differences in
8 leptospirosis outbreaks, especially during floods and unsuspected outbreaks. Only selected
9 components of the study will be performed in those areas if there are outbreaks.

10

11 **Study population**

12 The study population will include all undifferentiated fever cases either presented to the
13 outpatient department or admitted to medical wards/ICUs in TH Anuradhapura and TH
14 Peradeniya (main sites) and selected hospitals in Western, Sabaragamuwa, and Southern
15 provinces.

16

17 **Inclusion criteria**

- 18 • Age \geq 12 years.
- 19 • Temperature \geq 38°C.
- 20 • Self-reported fever \geq 2 days.

21

22 **Exclusion criteria**

- 23 • Fever with running nose without any other symptom or sign.
- 24 • Any patient with confirmed diagnosis/foci of infection as a cause for the fever.
- 25 • Traumatic or post-operative fever per physician discretion.
- 26 • Fever due to nosocomial infections.

1

2 Patient recruitment

3 Graduates with a Bachelor of Medicine and Bachelor of Surgery (MBBS) awaiting their
4 internship appointment and established registrars will be assigned to all four centers and directly
5 supervised on a daily basis. They will screen all febrile patients and perform directed physician
6 exams in the outpatient department, as well as on inpatients admitted to the medical wards. Once
7 the diagnostic facilities are established, we will inform all clinicians in the selected districts about
8 the available facilities. If they express interest, diagnostic facilities, including cultures to
9 determine species diversity will be provided.

10

11 Procedure

12 All possible undifferentiated fever cases will be interviewed and examined by the on-site
13 pre-intern medical officers and suspected leptospirosis cases (fulfilling inclusion and exclusion
14 criteria) will be referred to the study project. In the outpatient department (OPD), once the
15 medical officers complete the history taking and examination, the data collector will collect the
16 data. For inpatient patients, the pre-intern medical officer will screen all fever patients upon
17 admission to the ward, for the selection of eligible patients. In Anuradhapura, four medical units
18 are available and the study will be carried out in all four medical wards. In Peradeniya, a single
19 medical ward is available. Data collectors will visit all wards and ICUs daily for the purpose of
20 data collection. Once the routine ward procedures are completed, data will be collected. All
21 eligible patients will be provided an explanatory statement of the study. The data collector will
22 also explain the benefits and data confidentiality, as well as the right to withdraw from the study
23 at any given time. Once a patient is well informed, written consent will be obtained before
24 enrolment. Data will be collected in the ward, at the patient bed side to ensure the patient's
25 privacy and confidentiality, as a routine clinical procedure. In the outpatient department, a
26 separate location will be used to collect the data. Data will be collected using a fully structured,

1 interviewer-administered questionnaire. An additional clinical data check list will be used to
2 assess the clinical features. A daily follow-up will be performed for all hospitalized patients to
3 observe the clinical progress of the disease using a clinical checklist. The questionnaires and the
4 checklists will be adopted from previously published time-tested protocols.[22]

5 All patients will be given an appointment for follow up 3 weeks after the initial
6 assessment. To maximize patient follow-up, reminders and telephone calls will be used to contact
7 participants before their appointment, and the fee for transportation will be paid. Both blood (2
8 mL) and urine (10-15 mL) samples will be collected from patients during the follow-up.

10 **Sample size**

11 Assuming that at least 70% of patients are infected with same infective *Leptospira* strain in
12 a specific setting, and to detect at least a 20% difference between the OPD and hospitalized
13 patients, at least 62 leptospirosis patients with molecular identification are needed from each site.
14 This calculation was performed with a power of 80% and an alpha value of 0.05. Based on our
15 previous studies, the interpretable sequencing data are available for around 50% of confirmed
16 cases of leptospirosis[23] and leptospirosis accounts for 15% of acute undifferentiated fever.[24]
17 Based on these assumptions, the total number of febrile patients that is required from one sample
18 collection site for this study is 827. This number of patients is conservatively estimated and
19 feasible to obtain within the project period.

21 **Variables and epidemiological data**

22 We will be looking at socio-demographic, exposure and clinical data for the clinic-
23 epidemiological components of the study. The socio-demographic data will include age, sex,
24 ethnicity, religion, occupation, income and residence. These variables are usually the distance
25 determinants of leptospirosis and considered as important in determining the social determinants
26 of the disease. Exposure variables will be looking at several types of exposure. First set of

1 variables will include the residential and working environment and hosts. Next set will include
2 actual individual exposure during last three weeks. Clinical data will be obtained initially to
3 describe the presenting complains. All symptoms will be recorded as described by the patients.
4 We will be using a set of probing questions to clarify the presenting complains. Signs will be
5 documented after the physical examination by the clinically qualified data collector. If a sign is
6 documented after the admission by a treating physician it will also be included, even if it is not
7 demonstrable at the time of examination.

8

9 **Sample collection, procession, and storage procedure**

10 Blood and urine samples will be collected from patients on the day of admission to the
11 ward or upon presentation to the outpatient department. A total of 7 ml of blood will be collected
12 and a bed side inoculation of 2 to 4 drops (100-500 μ l) will be performed using two tubes
13 containing 9 ml of EMJH semisolid media with added antibiotics (5-Fluorouracil and Neomycin).
14 Collected blood added to EMJH media for culture will be incubated at 30°C in an incubator.

15 Venous blood (2.5 mL) will be collected in an EDTA tube and the remainder will be placed
16 into plain tubes for serum separation. For serum separation, the blood in the plain tubes will be
17 centrifuged at 1300 rpm for 10 minutes. The blood in the EDTA tubes will be used for PCR assay
18 and the serum samples for serological assays. Aliquots (500 μ l) will be prepared from the whole
19 blood and serum samples. These will then be frozen at -20°C or -80°C for short-term or long-term
20 storage, respectively. This procedure will be completed within 2 hours.

21 Clean catch mid-stream (10-15 mL) urine will be collected into a sterile wide mouth
22 container and processed within 2 hours of collection. Initially, the urine will be centrifuged at
23 3000 rpm for five minutes to sediment the white cells, epithelial cells, and other crystals. Next, the
24 supernatant will be separated and further centrifuged at 15000 rpm for 10 minutes. The sediment
25 obtained will be used for PCR studies and stored at -20°C until further use.[25-27] If the urine
26 cannot be processed during the specified time period, the pH of the urine will be adjusted to

1 approximately 7.4 using 1 M NaOH solution. Three weeks after the onset of fever, a follow-up
 2 blood sample (2 mL) will be collected in plain tubes for paired sera and 10-15 ml of urine will be
 3 collected for PCR assay.

4

5 **Disease confirmation**

6 Disease will be confirmed using a regionally optimized microscopic agglutination test
 7 (MAT), culture, and qPCR-evidence of the presence of *Leptospira* in the serum. The criteria for
 8 confirmed and probable cases of leptospirosis is presented in Table 1.[28]

9

10 **Table 1.** Criteria for the diagnosis of confirmed and probable cases of leptospirosis

Case	Definition
Confirmed	<p>Clinical signs and symptoms consistent with leptospirosis with any one of the following criteria:</p> <ol style="list-style-type: none"> 1. Four-fold increase in MAT titer in acute and convalescent serum samples. 2. MAT titer \geq 1:400 in single or paired serum samples. 3. Isolation of pathogenic <i>Leptospira</i> species from normally sterile sites. 4. Pathogenic <i>Leptospira</i> species DNA detected by PCR.
Probable case	<p>Clinical signs and symptoms consistent with leptospirosis with any one of the following criteria:</p> <ol style="list-style-type: none"> 1. Presence of IgM antibodies by enzyme-linked immunosorbent assay (ELISA) or dipstick. 2. MAT titer \geq 1:100 in single acute-phase serum sample (with no convalescent serum).

11

12 MAT

1 For this purpose, we will use the U.S. Center for Disease Control's (CDC) MAT panel with five
2 already available local strains obtained from the Royal Tropical Institute, Amsterdam (KIT). Once
3 the Sri Lankan isolates are obtained, a validation of best panel suitable for Sri Lanka will be
4 determined. MAT will be carried out in two main steps. First, the serum samples will be screened
5 at a titer of 1/50 using the MAT panel of 24 strains, which includes the five local strains. Positive
6 sera from the screening test will be subjected to a run out test with the serial dilution of sera from
7 1/50 to 1/3200. MAT evidence for seropositivity will be defined as one or more of the following:
8 seroconversion (1/100) from negative to positive; 4-fold increase in titer between acute-phase and
9 convalescent-phase (follow-up) samples; or a single titer of ≥ 400 .

10

11 Culture isolation of *Leptospira*

12 For the culture isolation, we adopted the previously validated protocol published by
13 Wuthiekanan et al. [29]. EMJH semisolid media will be prepared by adding 2.3 g of EMJH base,
14 1.5 g of bacteriological agar, and 100 mg of sodium pyruvate into 785 ml of distilled water, then
15 adjusting the pH to 7.4. The media will be autoclaved and cooled to around 50°C, Next, 100 ml of
16 *Leptospira* enrichment media and 100 ml of fetal bovine serum will be added to the media.[30-33]
17 To suppress the growth of possible contaminants, 5-Fluorouracil and Neomycin will be added, at
18 concentrations of 100 µg/ml and 25 µg/ml, respectively. The media inoculated with blood will be
19 inspected using dark field microscopy for the presence of motile *Leptospira*, initially after 3
20 weeks and then on a monthly basis. When a positive growth is detected, sub cultures will be
21 transferred into liquid and semisolid media. An aliquot will then be obtained and fixed with 5%
22 DMSO (Dimethyl Sulfoxide) and stored in -80°C. To maintain live cultures, the isolates will be
23 subcultured in liquid media on a bi-weekly basis and on semisolid media every 3 months.
24 Serotyping of the newly isolated *Leptospira* strains will be carried out at the Pasteur Institute,
25 France.

26

1 Quantitative PCR

2 *Diagnosis*

3 For the diagnosis, DNA will be extracted from whole blood, serum, and urine samples using the
 4 QIAamp DNA Blood Mini Kit (Qiagen, USA), according to the manufacturer's instructions. The
 5 extracted DNA will be quantified using an Invitrogen Qubit 4 Fluorometer. Two previously
 6 published quantitative PCR protocols targeting 16s ribosomal RNA and LipL32 genes will be used
 7 for the detection of pathogenic *Leptospira* DNA based on SYBR Green Chemistry (Table 2).[34]

8
 9 **Table 2.** Primers for the detection of *Leptospira* DNA in clinical samples

Primer/probe sequence	Annealing temperature	Complementary target species
Forward: 5'-AAG CAT TAC CGC TTG TGG TG-3' Reverse: 5'-GAA CTC CCA TTT CAG CGA TT-3'	60°C	lipL32 gene of pathogenic <i>Leptospira</i> spp.
Forward: 5'-TAA AGG CTC ACC AAG GCG AC-3' Reverse: 5'-TTA GCC GGT GCT TTA GGC AG-3'	60°C	16s gene of pathogenic <i>Leptospira</i> spp.

10

11 *Speciation*

12 To determine the *Leptospira* species in the positive cultures, a previously published quantitative
 13 PCR protocol based on SYBR Green Chemistry (Table 3) will be used (before sequencing).[35]
 14 This will facilitate the identification of *L. interrogans*, *L. borgpetersenii*, *L. kirschneri*, and *L.*
 15 *noguchii*.

16

1 **Table 3.** Primer pairs for detection of species

Primer/Probe sequence	Annealing temperature	Complementary target species
Forward: 5'-CTT GAG CCT GCG CGT TAY-3' Reverse: 5'-CCG ATA ATT CCA GCG AAG ATC-3'	63°C	secY gene of <i>L. interrogans</i>
Forward: 5'-GAT TCG GGT TAC AAT TAG ACC-3' Reverse: 5'-TTG ATC TAA CCG GAC CAT AGT-3'	65°C	ompL1 gene of <i>L. borgpetersenii</i>
Forward: 5'-CTG GCT TAA TCA ATG CTT CTG-3' Reverse: 5'-CTC TTT CGG TGA TCT GTT CC-3'	60°C	secY gene of <i>L. kirschneri</i>
Forward: 5'-TCA GGG TGT AAG AAA GGT TC-3' Forward: 5'-CAA AAT TAA AGA AGC AAA GA-3'	63°C	secY gene of <i>L. noguchii</i>

2
3 *Molecular studies*

4 For newly isolated *Leptospira*, whole genome sequencing will be performed using the
5 following two technologies: MinION Nanopore sequencing in the Leptospirosis Research
6 Laboratory (Faculty of Medicine and Allied Sciences, Rajarata University of Sri Lanka, India) and
7 PacBio third generation sequencing at the (University of Medicine Genomic for Institute
8 California, San Diego, USA).

9 BAS and BAX files containing all the DNA sequence information will be converted into
10 FASTA files. Prior to assembly, the quality (coverage) of the raw data will be assessed. Using the
11 PacBioEDA software, the quality summary of the data will be obtained. The CanuPacBio
12 assembly program will be used for genome assembly. The raw data of Bas/Bax files will be
13 converted into bam files using the bax2bam software. These bam files will be aligned to our
14 references using the Pbalngn software. The software Quiver will be used to polish the data. The
15 assembled data will be annotated using Prokka[36] and Roary[37], and annotations will be

1 inspected and curated using Artemis. The functional annotation will be performed using the
2 eggNOG and eggNOG MAPPER online tools.[38] The genomes of the Sri Lankan isolates will be
3 compared using MAUVE software. The organism will be roughly identified from the direct raw
4 data using KRAKEN.[39]

5 MLST will be used for the genotyping of the new isolates. Sri Lankan isolates will be
6 identified using three published MLST schemes for *Leptospira*. [40-42] Genetic similarity between
7 the isolates will be determined using SPLITSTREE.

9 **Taxonogenomics, pan-genome, and phylogenetic analyses**

10 To establish how this strain was related to other *Leptospira* strains, we will use several
11 genomic analysis tools. First, the 16S rRNA sequences will be used to construct a phylogeny.
12 High sequence identities ($\geq 97\%$) between the newly sequenced strain and previously identified
13 *Leptospira* strains will be preliminarily used as suggestive of phylogenetic relationships.
14 Accordingly, the 16S rRNA gene sequences of *Leptospira* spp. deposited in the GenBank
15 database will be acquired. Multiple sequence alignment based on 16S rRNA will be performed
16 using ClustalX v1.81. These results will be then used to construct the maximum likelihood tree
17 using MEGA v5.05. To evaluate clade support, we will perform a bootstrap analysis with 1,000
18 replicates. The relationship of each sequenced genome to the previously described or novel
19 *Leptospira* species will be determined according to the Overall Genetic Relatedness Indices
20 (OGRI), Average Nucleotide Identity (ANI), and the Average Amino Acid Identity (AAAI). The
21 indices will be automatically calculated using two-way BLA blastn and blastp. For the ANI
22 calculation, the default parameters shall be as follows: sequence identity cut-off, 30%; alignment
23 cut-off, 70%; query length, 1,020 bp.

25 **Data management and analysis**

1 Patient interviews and patient health records will be used as data sources. On-site data
2 entry will be performed in real-time for all the collected data. An EpiInfo database will be
3 prepared using cross-checks, field validation, and other in-built techniques available for data
4 quality improvement. The investigators will frequently visit the hospitals to cross-validate the data
5 collected. All databases will be stored on password-protected computers. The main database will
6 be stored at the Leptospirosis Research Laboratory of the Faculty of Medicine and Allied Science,
7 Rajarata University of Sri Lanka. Personal identification data will be removed from all the
8 databases, such that only aliquots and predesigned patient identifiers are available. Hardcopies of
9 the questionnaires will be archived using the standard protocols for archiving hard copies of
10 questionnaires. Only the investigators will have access to the database. The database will be
11 continuously updated with laboratory data using a linking patient identifier (Key variable). The
12 lab results will be generated for all samples daily, once a fully functioning lab is set up, and the
13 treating physicians will be informed about this over the phone. Separate laboratory registers will
14 be maintained for the receipt of samples and the delivery of the results.

15 For the missing data, case deletions and pairwise deletions will be carried out, based on the
16 amount of missing data. Proportions and 5% confidence intervals will be used to describe the
17 confirmed cases, diversity of infecting *Leptospira*, and sequelae. A Chi-square test will be used to
18 identify any trends and test significant differences in the *Leptospira* diversity in the different
19 microgeographical and clinical settings. Predictors of severe disease will be analyzed using a
20 logistic regression model. Model building will be performed using a conceptual hierarchy of
21 determinants, which we have previously proposed for leptospirosis. An online database for
22 *Leptospira* MLST will be used for typing analysis.

23

24 **Patient and public involvement**

25 The study was developed based on the patients' feedback regarding leptospirosis disease
26 burden, its impact on their lives, and in particular, the problems faced during illness. In previous

1 studies, we specifically explored patients as well as general public views on leptospirosis disease
2 and prevention, and used this information for the design of this study. Moreover, the results of this
3 study will be disseminated on a continuous basis for the patients. We have already conducted
4 several public awareness and health worker education workshops based on our findings.

6 ETHICS AND DISSEMINATION

7 Undifferentiated fever patients eligible for the study will be given an explanatory
8 statement of the study and written informed consent will be obtained before enrolment. Rapid
9 diagnostic kits will be used on site to assist treating physicians. qPCR diagnostic facilities will be
10 provided for all patients whenever the urgent tests are requested by treating physicians. All test
11 results will be informed to the patients and the wards. Ethical clearance for the study was obtained
12 from the Ethic Review Committees of Faculty of Medicine and Allied Sciences, Rajarata
13 University of Sri Lanka (ERC/2015/18).

14 All genomic data will be deposited in Gene Bank. Characterized serum samples will be
15 stored in -80C in the Faculty of Medicine and Allied Sciences, Rajarata University of Sri Lanka.
16 Data pertaining to this study will be available for researchers and policy makers on a reasonable
17 request address to the corresponding author. After the completion of work, data will be deposited
18 in a repository.

20 REFERENCES

- 21 1. WER: **Leptospirosis worldwide, 1999**. *Wkly Epidemiol Rec* 1999, **74**(29):237-242.
- 22 2. Costa F, Hagan JE, Calcagno J, Kane M, Torgerson P, Martinez-Silveira MS, Stein C,
23 Abela-Ridder B, Ko AI: **Global Morbidity and Mortality of Leptospirosis: A**
24 **Systematic Review**. *PLoS Negl Trop Dis* 2015, **9**(9):e0003898.
- 25 3. Taylor AJ, Paris DH, Newton PN: **A Systematic Review of the Mortality from**
26 **Untreated Leptospirosis**. *PLoS Negl Trop Dis* 2015, **9**(6):e0003866.
- 27 4. Agampodi S, Peacock SJ, Thevanesam V: **The potential emergence of leptospirosis in**
28 **Sri Lanka**. *Lancet Infect Dis* 2009, **9**(9):524-526.
- 29 5. Epidemiological Unit: **Selected notifiable diseases reported by Medical Officers of**
30 **Health**. *Weekly Epidemiological Report* 2009, **36**(1):4.
- 31 6. Epidemiological Unit: **Selected notifiable diseases reported by Medical Officers of**
32 **Health**. *Weekly Epidemiological Report* 2010, **37**(1):4.
- 33 7. Warnasekara JN, Agampodi S: **Leptospirosis in Sri Lanka**. *Sri Lankan Journal of*
34 *Infectious Diseases* 2017, **7**(2).

- 1 8. Pappas G, Papadimitriou P, Siozopoulou V, Christou L, Akritidis N: **The globalization of leptospirosis: worldwide incidence trends.** *Int J Infect Dis* 2008, **12**(4):351-357.
- 2 9. Agampodi SB, Peacock SJ, Thevanesam V, Nugegoda DB, Smythe L, Thaipadungpanit J, Craig SB, Burns MA, Dohnt M, Boonsilp S *et al*: **Leptospirosis outbreak in Sri Lanka in 2008: lessons for assessing the global burden of disease.** *Am J Trop Med Hyg* 2011, **85**(3):471-478.
- 3 10. Agampodi SB, Dahanayaka NJ, Bandaranayaka AK, Perera M, Priyankara S, Weerawansa P, Matthias MA, Vinetz JM: **Regional differences of leptospirosis in Sri Lanka: observations from a flood-associated outbreak in 2011.** *PLoS Negl Trop Dis* 2014, **8**(1):e2626.
- 4 11. Myers WP, Myers AP, Cox-Singh J, Lau HC, Mokuai B, Malley R: **Micro-geographic risk factors for malarial infection.** *Malaria journal* 2009, **8**:27.
- 5 12. Schellenberg JA, Newell JN, Snow RW, Mung'ala V, Marsh K, Smith PG, Hayes RJ: **An analysis of the geographical distribution of severe malaria in children in Kilifi District, Kenya.** *Int J Epidemiol* 1998, **27**(2):323-329.
- 6 13. Hassan AO, Amoo AOJ, Deji-Agboola AM, Adeleke MA, Muhibi MA, Hassan RO: **Microgeographical patterns of schistosomiasis and anthropometric indices of children in eko-ende south west, nigeria.** *Int J Biol Med Res* 2911, **2**(3):656-660.
- 7 14. Kloos H, Gazzinelli A, Van Zuyle P: **Microgeographical patterns of schistosomiasis and water contact behavior; examples from Africa and Brazil.** *Mem Inst Oswaldo Cruz* 1998, **93** Suppl 1:37-50.
- 8 15. Baliraine FN, Afrane YA, Amenity DA, Bonizzoni M, Menge DM, Zhou G, Zhong D, Vardo-Zalik AM, Githeko AK, Yan G: **High prevalence of asymptomatic plasmodium falciparum infections in a highland area of western Kenya: a cohort study.** *J Infect Dis* 2009, **200**(1):66-74.
- 9 16. Dissanayake CB, Chandrajith R: **Medical geochemistry of tropical environments.** *Earth-Science Reviews* 1999, **47**(3-4):219-258.
- 10 17. Naotunna C, Agampodi SB, Agampodi TC: **Etiological agents causing leptospirosis in Sri Lanka: A review.** *Asian Pac J Trop Med* 2016, **9**(4):390-394.
- 11 18. Agampodi SB, Moreno AC, Vinetz JM, Matthias MA: **Utility and limitations of direct multi-locus sequence typing on qPCR-positive blood to determine infecting Leptospira strain.** *Am J Trop Med Hyg* 2013, **88**(1):184-185.
- 12 19. Agampodi SB, Miatthias MA, Moreno AC, Vinetz JM: **Utility of Quantitative PCR in Leptospirosis Diagnosis: Association of Level of Leptospiremia and Clinical Manifestations in Sri Lanka.** *Clinical Infectious Disease* 2012, **In Press**.
- 13 20. Katz AR: **Quantitative polymerase chain reaction: filling the gap for early leptospirosis diagnosis.** *Clin Infect Dis* 2012, **54**(9):1256-1258.
- 14 21. Nityananda K, Harvey T: **Leptospirosis in Ceylon-Epidemiological and Laboratory Studies.** *Ceylon J Med Sci* 1971, **20**(1):5-14.
- 15 22. Agampodi SB, Nugegoda DB, Thevanesam V: **Determinants of leptospirosis in Sri Lanka: Study Protocol.** *BMC Infect Dis* 2010, **10**(1):332.
- 16 23. Agampodi SB, Matthias MA, Moreno AC, Vinetz JM: **Utility of quantitative polymerase chain reaction in leptospirosis diagnosis: association of level of leptospiremia and clinical manifestations in Sri Lanka.** *Clin Infect Dis* 2012, **54**(9):1249-1255.
- 17 24. Reller ME, Bodinayake C, Nagahawatte A, Devasiri V, Kodikara-Arachichi W, Strouse JJ, Flom JE, Dumler JS, Woods CW: **Leptospirosis as frequent cause of acute febrile illness in southern Sri Lanka.** *Emerg Infect Dis* 2011, **17**(9):1678-1684.
- 18 25. Lucchesi PM, Arroyo GH, Etcheverria AI, Parma AE, Seijo AC: **Recommendations for the detection of Leptospira in urine by PCR.** *Rev Soc Bras Med Trop* 2004, **37**(2):131-134.

- 1 26. Bal AE, Gravekamp C, Hartskeerl RA, De Meza-Brewster J, Korver H, Terpstra WJ:
2 **Detection of leptospire in urine by PCR for early diagnosis of leptospirosis.** *J Clin*
3 *Microbiol* 1994, **32**(8):1894-1898.
- 4 27. Van Eys GJ, Gravekamp C, Gerritsen MJ, Quint W, Cornelissen MT, Schegget JT,
5 Terpstra WJ: **Detection of leptospire in urine by polymerase chain reaction.** *J Clin*
6 *Microbiol* 1989, **27**(10):2258-2262.
- 7 28. World Health Organization: **Report of the second meeting of leptospirosis burden**
8 **epidemiology reference group.** In. Geneva: World Health Organization 2011: 1-34.
- 9 29. Wuthiekanun V, Chierakul W, Limmathurotsakul D, Smythe LD, Symonds ML, Dohnt
10 MF, Slack AT, Limpai boon R, Suputtamongkol Y, White NJ *et al*: **Optimization of**
11 **culture of Leptospira from humans with leptospirosis.** *J Clin Microbiol* 2007,
12 **45**(4):1363-1365.
- 13 30. Wuthiekanun V, Amornchai P, Langla S, Oyuchua M, Day NP, Limmathurotsakul D:
14 **Maintenance of leptospira species in leptospira Vanaporn Wuthiekanun agar.** *J Clin*
15 *Microbiol* 2014, **52**(12):4350-4352.
- 16 31. Wuthiekanun V, Amornchai P, Langla S, White NJ, Day NP, Limmathurotsakul D,
17 Peacock SJ: **Antimicrobial Disk Susceptibility Testing of Leptospira spp. Using**
18 **Leptospira Vanaporn Wuthiekanun (LVW) Agar.** *Am J Trop Med Hyg* 2015,
19 **93**(2):241-243.
- 20 32. Wuthiekanun V, White NJ, Amornchai P, Day NP, Limmathurotsakul D: **Quality controls**
21 **for antimicrobial disk diffusion testing on Leptospira Vanaporn Wuthiekanun agar.**
22 *Trans R Soc Trop Med Hyg* 2016, **110**(11):673-675.
- 23 33. Picardeau M, Bulach DM, Bouchier C, Zuerner RL, Zidane N, Wilson PJ, Creno S,
24 Kuczek ES, Bommezzadri S, Davis JC *et al*: **Genome sequence of the saprophyte**
25 **Leptospira biflexa provides insights into the evolution of Leptospira and the**
26 **pathogenesis of leptospirosis.** *PLoS ONE* 2008, **3**(2):e1607.
- 27 34. Backstedt BT, Buyuktanir O, Lindow J, Wunder EA, Reis MG, Usmani-Brown S, Ledizet
28 M, Ko A, Pal U: **Efficient Detection of Pathogenic Leptospire Using 16S Ribosomal**
29 **RNA.** *PLOS ONE* 2015, **10**(6):e0128913-e0128913.
- 30 35. Ferreira AS, Costa P, Rocha T, Amaro A, Vieira ML, Ahmed A, Thompson G, Hartskeerl
31 RA, Inacio J: **Direct detection and differentiation of pathogenic Leptospira species**
32 **using a multi-gene targeted real time PCR approach.** *PLoS One* 2014, **9**(11):e112312.
- 33 36. Seemann T: **Prokka: rapid prokaryotic genome annotation.** *Bioinformatics* 2014,
34 **30**(14):2068-2069.
- 35 37. Page AJ, Cummins CA, Hunt M, Wong VK, Reuter S, Holden MT, Fookes M, Falush D,
36 Keane JA, Parkhill J: **Roary: rapid large-scale prokaryote pan genome analysis.**
37 *Bioinformatics* 2015, **31**(22):3691-3693.
- 38 38. Huerta-Cepas J, Forslund K, Coelho LP, Szklarczyk D, Jensen LJ, von Mering C, Bork P:
39 **Fast Genome-Wide Functional Annotation through Orthology Assignment by**
40 **eggNOG-Mapper.** *Mol Biol Evol* 2017, **34**(8):2115-2122.
- 41 39. Wood DE, Salzberg SL: **Kraken: ultrafast metagenomic sequence classification using**
42 **exact alignments.** *Genome Biol* 2014, **15**(3):R46.
- 43 40. Varni V, Ruybal P, Lauthier JJ, Tomasini N, Brihuega B, Koval A, Caimi K:
44 **Reassessment of MLST schemes for Leptospira spp. typing worldwide.** *Infect Genet*
45 *Evol* 2014, **22**:216-222.
- 46 41. Ahmed N, Devi SM, Valverde Mde L, Vijayachari P, Machang'u RS, Ellis WA, Hartskeerl
47 RA: **Multilocus sequence typing method for identification and genotypic classification**
48 **of pathogenic Leptospira species.** *Ann Clin Microbiol Antimicrob* 2006, **5**:28.
- 49 42. Boonsilp S, Thaipadungpanit J, Amornchai P, Wuthiekanun V, Bailey MS, Holden MT,
50 Zhang C, Jiang X, Koizumi N, Taylor K *et al*: **A single multilocus sequence typing**
51 **(MLST) scheme for seven pathogenic Leptospira species.** *PLoS Negl Trop Dis* 2013,
52 **7**(1):e1954.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2 **AUTHORS' CONTRIBUTIONS**

3 JMV and SBA drafted the initial protocol. YPJNW, JMDDJ and RMISKS are responsible
4 for the detailed design, field/ laboratory work analysis and interpretation of objectives 1-3, 4 and 5
5 respectively. CDG, SAMK and SHS helped in design, field, hospital and laboratory work. MM
6 participated in scientific design and guided all laboratory components. All authors have read and
7 approved the manuscript.

8
9 **FUNDING**

10 This project is the Sri Lankan component of a multi country study funded by the NIAID of
11 the National Institutes of Health under award number U19AI115658. Funders had no role in the
12 design, execution, analyses, data interpretation, or decision to submit results.

13
14 **CONFLICTS OF INTERESTS**

15 The authors declare that they have no competing interests.

16
17 **WORD COUNT**

18 3791

1 **1 FIGURES**

2
3
4 **2 Figure 1: Locations of study sites.**

5
6 **3**

7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Study sites

147x201mm (72 x 72 DPI)

BMJ Open

Study protocol: Characterizing the clinical, epidemiological, and etiological aspects of leptospirosis in Sri Lanka

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-027850.R2
Article Type:	Protocol
Date Submitted by the Author:	11-Jul-2019
Complete List of Authors:	Agampodi, Suneth; Rajarata University, Department of Community Medicine Warnasekara, Janith; Rajarata University of Sri Lanka Faculty of Medicine and Allied Sciences, Department of Community Medicine Jayasundara, Dinesha; Rajarata University of Sri Lanka Faculty of Medicine and Allied Sciences, Department of Microbiology Senawirathna, Indika; Rajarata University of Sri Lanka Faculty of Medicine and Allied Sciences, Biochemistry Gamage, Chandika; University of Peradeniya Faculty of Medicine, Microbiology Kularatne, Senanayake; University of Peradeniya Faculty of Medicine, Medicine Siribaddana, Sisira; Rajarata University of Sri Lanka Faculty of Medicine and Allied Sciences, Department of Medicine Maththias, Michael; Yale University School of Medicine Vinetz, Joseph; Yale University School of Medicine
Primary Subject Heading:	Infectious diseases
Secondary Subject Heading:	Epidemiology, Global health, Public health, Infectious diseases
Keywords:	Leptospirosis, Sri Lanka, Leptospira, Isolates, Whole genome sequencing, Clinical disease

SCHOLARONE™
Manuscripts

1 **1 Study protocol: Characterizing the clinical, epidemiological, and etiological aspects of**
2 **2 leptospirosis in Sri Lanka**

3
4
5
6
7 4 Agampodi SB^{1*}, Warnasekara YPJN¹, Jayasundara JMDD², Senawirathna RMISK³, Gamage
8 CD⁴, Kularatne SAM⁵, Siribaddana SH⁶, Maththias M⁷, Vinetz JV⁷
9

10
11
12 7 ¹ Department of Community Medicine, Faculty of Medicine and Allied Sciences, Rajarata
13 University of Sri Lanka
14

15 9 ² Department of Microbiology, Faculty of Medicine and Allied Sciences, Rajarata University of
16 Sri Lanka
17

18 11 ³ Department of Biochemistry, Faculty of Medicine and Allied Sciences, Rajarata University of
19 Sri Lanka
20

21 13 ⁴ Department of Microbiology, Faculty of Medicine, University of Peradeniya
22

23 14 ⁵ Department of Medicine, Faculty of Medicine, University of Peradeniya
24

25 15 ⁶ Department of Medicine, Faculty of Medicine and Allied Sciences, Rajarata University of Sri
26 Lanka
27

28 17 ⁷ Yale School of Medicine, Section of Infectious Diseases, Department of Internal Medicine
29 New Haven, CT 06520
30

31 18
32 19
33 20 ASB: sunethagampodi@yahoo.com,

34 21 WYPJN: jwarnasekara@yahoo.com

35 22 JJMDD: dineshajayasundara@yahoo.com

36 23 SRMISK: irathnabahu@gmail.com

37 24 GCD: chandika@pdn.ac.lk

38 25 KSAM: samkul@sltnet.lk

39 26 SSH: sisira.siribaddana@gmail.com

40 27 MM: mikematthias34@icloud.com

41 28 VJV: joseph.vinetz@yale.edu
42
43
44
45
46
47
48
49
50

51 30 *Corresponding author.
52
53
54
55
56
57
58
59
60

1 ABSTRACT

2 **Introduction:** Sri Lanka has one of the highest incidences of leptospirosis worldwide. We
3 hypothesized that different geographical locations and patient context will have a distinct molecular
4 epidemiology of leptospirosis, based on microgeographic characteristics related to regiona-specific
5 *Leptospira* predominance. Our objective is to characterize the clinical, epidemiological, and
6 molecular aspects of leptospirosis in Sri Lanka to understand disease progression, risk factors, and
7 obtain isolates of *Leptospira*. **Methods and Analysis:** We designed a multi-center prospective
8 study in Sri Lanka to recruit undifferentiated febrile patients and conduct follow-ups during hospital
9 stays. Patients will be recruited from outpatient departments and medical wards. This study will be
10 conducted at two main sites (Anuradhapura and Peradeniya) and several additional sites
11 (Awissawella, Ratnapura and Polonnaruwa). Blood and urine will be collected from patients on the
12 day of admission to the ward or presentation to the outpatient department. Bedside inoculation of 2
13 and 4 drops of venous blood will be performed with EMJH semisolid media supplemented with
14 antibiotics. Regionally optimized microscopic agglutination test, culture, and qPCR-evidence will
15 be performed to confirm the presence of *Leptospira* in blood, which in turn will confirm the
16 presence of disease. Whole genome sequencing will be carried out for all isolates recovered from
17 patients. Multi locus sequence typing (MLST) will be used for the genotyping of new isolates. Sri
18 Lankan isolates will be identified using three published MLST schemes for *Leptospira*. **Ethics and**
19 **Dissemination:** Ethical clearance for the study was obtained from Ethics Review Committees
20 (ERC), Medicine and Allied Sciences (FMAS), Rajarata University of Sri Lanka (RUSL) and
21 University of Peradeniya. All genomic data generated through this project will be available at
22 GenBank. Anonymized data will be deposited at the ERC, FMAS, RUSL.

1 STRENGTHS AND LIMITATIONS OF THIS STUDY

- 2 • This is a multi-center study involving wet and dry zones, low and highlands and high
3 endemic and low endemic areas of the country covering different geographical and climate
4 zones to provide a better understanding of leptospirosis in Sri Lanka.
- 5 • We will use a prospective study design focusing on culture isolation as a main aim with
6 specific protocols for the particular objective to describe the strain diversity of *Leptospira*
7 *spp.* in Sri Lanka.
- 8 • Clinical and epidemiological data will be collected as primary data to ensure high quality
9 data using clinically trained health professionals.
- 10 • Since *Leptospira* are fastidious organisms, the culture yield will be low and linking the
11 clinical disease with isolated *Leptospira* may be partly confounded by the growth
12 potentials of different *Leptospira*.
- 13 • Since PCR and culture-based methods are typically valid only during the first 7-10 days of
14 the illness and late presentations may lead to reduce sensitivity of these tests, MAT is best
15 interpreted with paired samples, and a lack of convalescent samples will impair the
16 interpretation of MAT results.

1 INTRODUCTION

2 Leptospirosis is a globally widespread, neglected, and emerging zoonotic disease[1] with
3 estimated 1.03 million cases and 58,900 annual deaths attributed to the disease.[2] An average of
4 2.9 million daily adjusted life years (DALYs) are estimated to be lost every year due to
5 leptospirosis.[3] Emerging leptospirosis mostly affects vulnerable communities living in resource-
6 poor settings. Often, the disease is either not suspected or is under or misdiagnosed due to the need
7 for laboratory resources to confirm leptospirosis; typically, such resources are neither accessible
8 nor affordable. From the clinical perspective, a better understanding of the clinical disease
9 associated with diverse *Leptospira* species is required and superior diagnostics are needed to
10 prevent severe complications and death. From the public health perspective, the lack of reliable and
11 efficient diagnostic tests makes assessing the burden of disease—whether regionally or globally—
12 difficult.

13 Sri Lanka has emerged as a country with a high incidence of leptospirosis since 2007[4] and in
14 2008, the total number of clinically suspected cases reported to the surveillance system was 7,406
15 with 204 deaths.[5] In 2009, 4980 cases and 145 deaths were reported[6], and the outbreak persisted
16 until 2013 with more than 4000 reported cases each year.[7] The probable case incidence during
17 this time period was more than 20 per 100,000 population, indicating that Sri Lanka has one of the
18 highest reported incidences of leptospirosis worldwide.[8] Our extensive work on the 2008 outbreak
19 suggested that clinical diagnosis of leptospirosis is highly inaccurate, since as much as 40% of the
20 leptospirosis patients are misdiagnosed in hospitals.[9] However, all Sri Lankan studies, including
21 our previous study, have the same drawback, as observed in most of the published reports in global
22 literature: hospital admission bias, where a large number of patients with leptospirosis may have
23 been treated as outpatients, which leads to a severe underestimate of the actual disease burden. A
24 precise disease burden estimate requires seroprevalence studies coupled with population-based
25 incidence studies.

26 Our studies on the 2011 outbreak of leptospirosis in Anuradhapura showed that the molecular
27 epidemiology, disease transmission, and clinical manifestations of this outbreak were different from

1 those observed in Central Province (wet zone) in 2008.[10] One of the main concerns regarding
2 these marked variations in the *Leptospira* strain and the clinical disease was whether this was due
3 to microgeographical variations, environmental conditions, or reservoir mammal infection. It has
4 been shown for other diseases such as malaria[11, 12] and schistosomiasis[13-15], that
5 microgeography may have a major influence on disease epidemiology. Geochemistry is a well-
6 known and major contributory factor in human health.[16] Despite the extensive literature available
7 on leptospirosis, studies on the microgeographic variation of *Leptospira* are scarce.

8 A systematic review performed on Sri Lankan isolates showed that more than 40 strains
9 from 20 serovars of *Leptospira* have been reported from Sri Lanka.[17] Our previous studies on the
10 2008 and 2011 outbreaks of leptospirosis in Sri Lanka expanded the knowledge of circulating
11 *Leptospira* and were consistent with a diversity of *Leptospira* infection in Sri Lanka. We showed
12 that in the 2008 outbreak, *L. interrogans* was the predominant species, compared to the post-flood
13 outbreak in 2011, in which *L. kirschneri* was the predominant species. However, the molecular
14 epidemiology of *Leptospira* species in endemic settings remains unknown in Sri Lanka. In addition
15 to the STNPCR method, for the first time, we showed that previously published multi locus
16 sequence typing (MLST) schemes could be used with modifications for direct patients samples to
17 study the genetic diversity of infecting *Leptospira* species in resource-poor settings, where the
18 facilities needed to perform cultures and isolations are minimal.[18]

19 One of the most important conclusions we draw from our published work is that qPCR is
20 promising as a clinical diagnostic tool in the diagnosis of leptospirosis during the acute phase, with
21 a wider window of positivity than previously noted.[19] The editorial by Katz[20] endorsed the
22 qPCR approach but also emphasized the need for a prospective evaluation of this method. However,
23 most countries with high leptospirosis burdens still find it prohibitively expensive to have molecular
24 based methods for rapid diagnosis, in terms of both the costs and logistics.

25 Disease burden assessment, public health interventions, and clinical management of
26 leptospirosis are challenges due to the lack of diagnostic facilities. Any population-based attempt

1 to estimate the disease burden is often limited by the unavailability of diagnostic tests or the poor
2 performance of the available diagnostic tests. The development of diagnostic tests that are both
3 global and country-specific requires knowledge on circulating serovars. Furthermore, well-
4 characterized samples are required with species and subspecies level identification of infecting
5 *Leptospira* backed by culture isolations. In Sri Lanka, a culture isolation of *Leptospira* has not been
6 reported since the 1970s. Even though we showed the microgeographical changes of leptospirosis
7 in 2014,[10] no prospective studies have been conducted in a Sri Lankan cohort to primarily identify
8 the disease diversity with specific research design. We hypothesized that a different study site and
9 patient context—inpatient vs. outpatient—will have a distinct molecular epidemiology of
10 leptospirosis, based on microgeographic characteristics related to region-specific *Leptospira*
11 predominance, clinical characteristics related to pathogenesis/virulence potential of specific
12 *Leptospira* species, strains, serovars, and the acquisition of infection related to occupational and
13 activities of daily living, reflecting different environmental exposure contexts. Based on these
14 background analyses and hypotheses, the objectives of the present study were as follows:

- 15 1. To determine the prevalence of leptospirosis among undifferentiated febrile patients
16 (inpatient and outpatient) in contrasting geographical settings in Sri Lanka.
- 17 2. To describe the full clinical spectrum of leptospirosis in patients infected with *Leptospira*.
- 18 3. To determine the predictors of leptospirosis progression using a nested case control
19 approach among febrile patients, both inpatient and ambulatory.
- 20 4. To determine the *Leptospira* species and type diversity in different geographical settings
21 in Sri Lanka.
- 22 5. To characterize Sri Lankan *Leptospira* using MLST and whole genome sequencing
23 methods.
- 24 6. To have a well-characterized collection of serum, whole blood, and urine samples for the
25 future development and validation of leptospirosis diagnostics.

1 METHODS AND ANALYSIS

2 Study sites

3 This study will be performed in four primary subject enrolment/data collection centers in
4 two main contrasting sites: Kandy and Anuradhapura. In addition, a small component of the study
5 will be carried out in Sabaragamuwa, Western, North Central, and Southern provinces for species
6 diversity (Figure 1). Kandy and Anuradhapura was selected based on our previous observations of
7 *Leptospira* diversity in these two settings, supported by historically distant identification of diverse
8 *Leptospira* in Sri Lanka (1960s)[21]. Since no recent studies have been conducted, this project will
9 yield up-to-date information at the molecular and genomically-determined taxonomical levels in
10 addition to conventional methods of identifying *Leptospira*. The initial focus is on Anuradhapura,
11 located in North Central province of Sri Lanka, in the dry zone of the country. The annual rainfall
12 is 1,200-1,600 mm, with a mean annual temperature of ~30°C. In Anuradhapura, paddy farming is
13 carried out by traditional, full-time farmers and constitutes the main mode of income. Cattle, water
14 buffalo, certain rodent species—well-known sources of *Leptospira* transmission—are found in and
15 around the paddy fields. Paddy fields are large and well maintained. There are no wetlands or
16 marshy lands in these areas, except the paddy fields during working seasons. Paddy field work
17 depends on irrigation systems, such that, between farming seasons, the paddy fields become
18 completely dry. Other risk factors for acquiring leptospirosis include daily activities involved in
19 living in economically poor conditions, for example living in proximity to dogs and rodents in
20 houses and neighborhoods and the wearing of shoes that are often no more than sandals.

21 The soil structure, water quality/hardness, and ecological systems in Anuradhapura contrast
22 with those of the wet zone of Sri Lanka. Kandy (another historic site in Sri Lanka/Ceylon, the
23 cultural capital of the country since ancient times) is situated in the wet zone, with over 3,000 mm
24 of rainfall, and is located in the middle, hilly parts of the country. Paddy farming in this area is
25 based on rainwater and the paddy fields remain wet throughout the year. These are small fields
26 adjacent to wildlife and the soil and ecological structure is different from that in Anuradhapura.
27 Nonetheless, the economic conditions of residents in this region are poor and rural, such that rodent-

1 and dog-transmitted *Leptospira* in the context of activities of daily living is likely common but
2 completely unexplored.

3 The purpose of including additional sites is primarily to identify differences in leptospirosis
4 outbreaks, especially during floods and unsuspected outbreaks. Only selected components of the
5 study will be performed in those areas if there are outbreaks.

6 **Study population**

7 The study population will include all undifferentiated fever cases either presented to the
8 outpatient department or admitted to medical wards/ICUs in TH Anuradhapura and TH Peradeniya
9 (main sites) and selected hospitals in Western, Sabaragamuwa, and Southern provinces.

10 **Inclusion criteria**

- 11 • Age \geq 12 years.
- 12 • Temperature \geq 38°C.
- 13 • Self-reported fever \geq 2 days.

14 **Exclusion criteria**

- 15 • Fever with running nose without any other symptom or sign.
- 16 • Any patient with confirmed diagnosis/foci of infection as a cause for the fever.
- 17 • Traumatic or post-operative fever per physician discretion.
- 18 • Fever due to nosocomial infections.

19 **Patient recruitment**

20 Graduates with a Bachelor of Medicine and Bachelor of Surgery (MBBS) awaiting their
21 internship appointment and established registrars will be assigned to all four centers and directly
22 supervised on a daily basis. They will screen all febrile patients and perform directed physician

1 exams in the outpatient department, as well as on inpatients admitted to the medical wards. Once
2 the diagnostic facilities are established, we will inform all clinicians in the selected districts about
3 the available facilities. If they express interest, diagnostic facilities, including cultures to determine
4 species diversity will be provided.

6 Procedure

7 All possible undifferentiated fever cases will be interviewed and examined by the on-site
8 pre-intern medical officers and suspected leptospirosis cases (fulfilling inclusion and exclusion
9 criteria) will be referred to the study project. In the outpatient department (OPD), once the medical
10 officers complete the history taking and examination, the data collector will collect the data. For
11 inpatient patients, the pre-intern medical officer will screen all fever patients upon admission to the
12 ward, for the selection of eligible patients. In Anuradhapura, four medical units are available and
13 the study will be carried out in all four medical wards. In Peradeniya, a single medical ward is
14 available. Data collectors will visit all wards and ICUs daily for the purpose of data collection. Once
15 the routine ward procedures are completed, data will be collected. All eligible patients will be
16 provided an explanatory statement of the study. The data collector will also explain the benefits and
17 data confidentiality, as well as the right to withdraw from the study at any given time. Once a patient
18 is well informed, written consent will be obtained before enrolment. Data will be collected in the
19 ward, at the patient bed side to ensure the patient's privacy and confidentiality, as a routine clinical
20 procedure. In the outpatient department, a separate location will be used to collect the data. Data
21 will be collected using a fully structured, interviewer-administered questionnaire. Once the initial
22 data collation is completed, all biological sample will be collected (see the section on sample
23 collection, procession, and storage procedure). An additional clinical data check list will be used to
24 assess the clinical features. A daily follow-up will be performed for all hospitalized patients to
25 observe the clinical progress of the disease using a clinical checklist. The questionnaires and the
26 checklists will be adopted from previously published time-tested protocols.[22]

1 All patients will be given an appointment for follow-up 3 weeks after the initial assessment.
2
3
4 2 To maximize patient follow-up, reminders and telephone calls will be used to contact participants
5
6 3 before their appointment, and the fee for transportation will be paid. The main purpose of the follow-
7
8 4 up would be to obtain a sample for disease confirmation.
9

10 5 11 12 13 6 **Sample size**

14
15 7 Assuming that at least 70% of patients are infected with same infective *Leptospira* strain in
16
17 8 a specific setting, at least 24 leptospirosis patients with molecular identification are needed from
18
19 9 each site. This calculation was performed with a power of 80% and an alpha value of 0.05. Based
20
21 10 on our previous studies, the interpretable sequencing data are available for around 50% of confirmed
22
23 11 cases of leptospirosis [23] and leptospirosis accounts for 15% of acute undifferentiated fever.[24]
24
25 12 Based on these assumptions, the total number of febrile patients that is required from one sample
26
27 13 collection site for this study is 320. This number of patients is conservatively estimated and feasible
28
29 14 to obtain within the project period.
30
31
32
33
34
35

36 16 **Variables and epidemiological data**

37
38 17 We will be looking at socio-demographic, exposure and clinical data for the clinic-
39
40 18 epidemiological components of the study. The socio-demographic data will include age, sex,
41
42 19 ethnicity, religion, occupation, income and residence. These variables are usually the distance
43
44 20 determinants of leptospirosis and considered as important in determining the social determinants
45
46 21 of the disease. Exposure variables will be looking at several types of exposure. First set of
47
48 22 variables will include the residential and working environment and hosts. Next set will include
49
50 23 actual individual exposure during last three weeks. Clinical data will be obtained initially to
51
52 24 describe the presenting complains. All symptoms will be recorded as described by the patients.
53
54 25 We will be using a set of probing questions to clarify the presenting complains. Signs will be
55
56 26 documented after the physical examination by the clinically qualified data collector. If a sign is
57
58
59
60

1 documented after the admission by a treating physician it will also be included, even if it is not
2 demonstrable at the time of examination.
3
4

5
6
7

8 **Sample collection, procession, and storage procedure** 9

10 Blood and urine samples will be collected from patients on the day of admission to the ward
11 or upon presentation to the outpatient department. A total of 7 ml of blood will be collected and a
12 bed side inoculation of 2 to 4 drops (100-500 µl) will be performed using two tubes containing 9
13 ml of EMJH semisolid media with added antibiotics (5-Fluorouracil and Neomycin). Collected
14 blood added to EMJH media for culture will be incubated at 30°C in an incubator.
15
16
17
18
19
20
21

22 Venous blood (2.5 mL) will be collected in an EDTA tube and the remainder will be placed
23 into plain tubes for serum separation. For serum separation, the blood in the plain tubes will be
24 centrifuged at 1300 rpm for 10 minutes. The blood in the EDTA tubes will be used for PCR assay
25 and the serum samples for serological assays. Aliquots (500 µl) will be prepared from the whole
26 blood and serum samples. These will then be frozen at -20°C or -80°C for short-term or long-term
27 storage, respectively. This procedure will be completed within 2 hours.
28
29
30
31
32
33
34
35

36 Clean catch mid-stream (10-15 mL) urine will be collected into a sterile wide mouth
37 container and processed within 2 hours of collection. Initially, the urine will be centrifuged at 3000
38 rpm for five minutes to sediment the white cells, epithelial cells, and other crystals. Next, the
39 supernatant will be separated and further centrifuged at 15000 rpm for 10 minutes. The sediment
40 obtained will be used for PCR studies and stored at -20°C until further use.[25-27] The available
41 protocols for qPCR based urine analysis will be tested and optimized. If the urine cannot be
42 processed during the specified time period, the pH of the urine will be adjusted to approximately
43 7.4 using 1 M NaOH solution. Three weeks after the onset of fever, a follow-up blood sample (2
44 mL) will be collected in plain tubes for paired sera and 10-15 ml of urine will be collected for PCR
45 assay.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 Disease confirmation

2 Disease will be confirmed using a regionally optimized microscopic agglutination test
3 (MAT), culture, and qPCR-evidence of the presence of *Leptospira* in the serum. The criteria for
4 confirmed and probable cases of leptospirosis is presented in Table 1.[28]

5

6 **Table 1.** Criteria for the diagnosis of confirmed and probable cases of leptospirosis

Case	Definition
Confirmed	<p>Clinical signs and symptoms consistent with leptospirosis with any one of the following criteria:</p> <ol style="list-style-type: none"> 1. Four-fold increase in MAT titer in acute and convalescent serum samples. 2. MAT titer \geq 1:400 in single or paired serum samples. 3. Isolation of pathogenic <i>Leptospira</i> species from normally sterile sites. 4. Pathogenic <i>Leptospira</i> species DNA detected by PCR.
Probable case	<p>Clinical signs and symptoms consistent with leptospirosis with any one of the following criteria:</p> <ol style="list-style-type: none"> 1. Presence of IgM antibodies by enzyme-linked immunosorbent assay (ELISA) or dipstick. 2. MAT titer \geq 1:100 in single acute-phase serum sample (with no convalescent serum).

7

8 MAT

9 For this purpose, we will use the U.S. Center for Disease Control's (CDC) MAT panel with five
10 already available local strains obtained from the Royal Tropical Institute, Amsterdam (KIT). Once
11 the Sri Lankan isolates are obtained, a validation of best panel suitable for Sri Lanka will be
12 determined. MAT will be carried out in two main steps. First, the serum samples will be screened

1 at a titer of 1/50 using the MAT panel of 24 strains, which includes the five local strains. Positive
2 sera from the screening test will be subjected to a run out test with the serial dilution of sera from
3 1/50 to 1/3200. MAT evidence for seropositivity will be defined as one or more of the following:
4 seroconversion from negative to positive ($<1/50$ - $>1/50$); 4-fold increase in titer between acute-
5 phase and convalescent-phase (follow-up) samples; or a single titer of ≥ 400 .

7 Culture isolation of *Leptospira*

8 For the culture isolation, we adopted the previously validated protocol published by
9 Wuthiekanan et al. [29]. EMJH semisolid media will be prepared by adding 2.3 g of EMJH base,
10 1.5 g of bacteriological agar, and 100 mg of sodium pyruvate into 785 ml of distilled water, then
11 adjusting the pH to 7.4. The media will be autoclaved and cooled to around 50°C, Next, 100 ml of
12 *Leptospira* enrichment media and 100 ml of fetal bovine serum will be added to the media.[30-33]
13 To suppress the growth of possible contaminants, 5-Fluorouracil and Neomycin will be added, at
14 concentrations of 100 $\mu\text{g/ml}$ and 25 $\mu\text{g/ml}$, respectively. The media inoculated with blood will be
15 inspected using dark field microscopy for the presence of motile *Leptospira*, initially after 3 weeks
16 and then on a monthly basis. When a positive growth is detected, sub cultures will be transferred
17 into liquid and semisolid media. An aliquot will then be obtained and fixed with 5% DMSO
18 (Dimethyl Sulfoxide) and stored in -80°C. To maintain live cultures, the isolates will be subcultured
19 in liquid media on a bi-weekly basis and on semisolid media every 3 months. Serotyping of the
20 newly isolated *Leptospira* strains will be carried out at the Pasteur Institute, France.

22 Quantitative PCR

23 *Diagnosis*

24 For the diagnosis, DNA will be extracted from whole blood, serum, and urine samples using the
25 QIAamp DNA Blood Mini Kit (Qiagen, USA), according to the manufacturer's instructions. The
26 extracted DNA will be quantified using an Invitrogen Qubit 4 Fluorometer. Two previously

1 published quantitative PCR protocols targeting 16s ribosomal RNA and LipL32 genes will be used
 2 for the detection of pathogenic *Leptospira* DNA based on SYBR Green Chemistry (Table 2).[34]

3
 4 **Table 2.** Primers for the detection of *Leptospira* DNA in clinical samples

Primer/probe sequence	Annealing temperature	Complementary target species
Forward: 5'-AAG CAT TAC CGC TTG TGG TG-3' Reverse: 5'-GAA CTC CCA TTT CAG CGA TT-3'	60°C	lipL32 gene of pathogenic <i>Leptospira</i> spp.
Forward: 5'-TAA AGG CTC ACC AAG GCG AC-3' Reverse: 5'-TTA GCC GGT GCT TTA GGC AG-3'	60°C	16s gene of pathogenic <i>Leptospira</i> spp.

5 6 *Speciation*

7 To determine the *Leptospira* species in the positive cultures, a previously published quantitative
 8 PCR protocol based on SYBR Green Chemistry (Table 3) will be used (before sequencing).[35]

9 This will facilitate the identification of *L. interrogans*, *L. borgpetersenii*, *L. kirschneri*, and *L.*
 10 *noguchii*.

11
 12 **Table 3.** Primer pairs for detection of species

Primer/Probe sequence	Annealing temperature	Complementary target species

Forward: 5'-CTT GAG CCT GCG CGT TAY-3' Reverse: 5'-CCG ATA ATT CCA GCG AAG ATC-3'	63°C	secY gene of <i>L. interrogans</i>
Forward: 5'-GAT TCG GGT TAC AAT TAG ACC-3' Reverse: 5'-TTG ATC TAA CCG GAC CAT AGT-3'	65°C	ompL1 gene of <i>L. borgpetersenii</i>
Forward: 5'-CTG GCT TAA TCA ATG CTT CTG-3' Reverse: 5'-CTC TTT CGG TGA TCT GTT CC-3'	60°C	secY gene of <i>L. kirschneri</i>
Forward: 5'-TCA GGG TGT AAG AAA GGT TC-3' Forward: 5'-CAA AAT TAA AGA AGC AAA GA-3'	63°C	secY gene of <i>L. noguchii</i>

Molecular studies

For newly isolated *Leptospira*, whole genome sequencing will be performed using the following two technologies: MinION Nanopore sequencing in the Leptospirosis Research Laboratory (Faculty of Medicine and Allied Sciences, Rajarata University of Sri Lanka, India) and PacBio third generation sequencing at the (of University) Medicine Genomic for Institute California, San Diego, USA).

BAS and BAX files containing all the DNA sequence information will be converted into FASTA files. Prior to assembly, the quality (coverage) of the raw data will be assessed. Using the PacBioEDA software, the quality summary of the data will be obtained. The CanuPacBiO assembly program will be used for genome assembly. The raw data of Bas/Bax files will be converted into bam files using the bax2bam software. These bam files will be aligned to our references using the Pbalngn software. The software Quiver will be used to polish the data. The assembled data will be annotated using Prokka[36] and Roary[37], and annotations will be inspected and curated using Artemis. The functional annotation will be performed using the eggNOG and eggNOG MAPPER online tools.[38] The genomes of the Sri Lankan isolates will be compared using MAUVE software. The organism will be roughly identified from the direct raw data using KRAKEN.[39]

1 MLST will be used for the genotyping of the new isolates. Sri Lankan isolates will be
2 identified using three published MLST schemes for *Leptospira*.^[40-42] Genetic similarity between
3 the isolates will be determined using SPLITSTREE.

5 **Taxonogenomics, pan-genome, and phylogenetic analyses**

6 To establish how this strain was related to other *Leptospira* strains, we will use several
7 genomic analysis tools. First, the 16S rRNA sequences will be used to construct a phylogeny. High
8 sequence identities ($\geq 97\%$) between the newly sequenced strain and previously identified
9 *Leptospira* strains will be preliminarily used as suggestive of phylogenetic relationships.
10 Accordingly, the 16S rRNA gene sequences of *Leptospira* spp. deposited in the GenBank database
11 will be acquired. Multiple sequence alignment based on 16S rRNA will be performed using
12 ClustalX v1.81. These results will be then used to construct the maximum likelihood tree using
13 MEGA v5.05. To evaluate clade support, we will perform a bootstrap analysis with 1,000 replicates.
14 The relationship of each sequenced genome to the previously described or novel *Leptospira* species
15 will be determined according to the Overall Genetic Relatedness Indices (OGRI), Average
16 Nucleotide Identity (ANI), and the Average Amino Acid Identity (AAAI). The indices will be
17 automatically calculated using two-way BLA blastn and blastp. For the ANI calculation, the default
18 parameters shall be as follows: sequence identity cut-off, 30%; alignment cut-off, 70%; query
19 length, 1,020 bp.

21 **Data management and analysis**

22 Patient interviews and patient health records will be used as data sources. On-site data entry
23 will be performed in real-time for all the collected data. An EpiInfo database will be prepared using
24 cross-checks, field validation, and other in-built techniques available for data quality improvement.
25 The investigators will frequently visit the hospitals to cross-validate the data collected. All databases
26 will be stored on password-protected computers. The main database will be stored at the

1 Leptospirosis Research Laboratory of the Faculty of Medicine and Allied Science, Rajarata
2 University of Sri Lanka. Personal identification data will be removed from all the databases, such
3 that only aliquots and predesigned patient identifiers are available. Hardcopies of the questionnaires
4 will be archived using the standard protocols for archiving hard copies of questionnaires. Only the
5 investigators will have access to the database. The database will be continuously updated with
6 laboratory data using a linking patient identifier (Key variable). The lab results will be generated
7 for all samples daily, once a fully functioning lab is set up, and the treating physicians will be
8 informed about this over the phone. Separate laboratory registers will be maintained for the receipt
9 of samples and the delivery of the results.

10 For the missing data, case deletions and pairwise deletions will be carried out, based on the
11 amount of missing data. Proportions and 5% confidence intervals will be used to describe the
12 confirmed cases, diversity of infecting *Leptospira*, and sequelae. A Chi-square test will be used to
13 identify any trends and test significant differences in the *Leptospira* diversity in the different
14 microgeographical and clinical settings. Predictors of severe disease will be analyzed using a
15 logistic regression model. Model building will be performed using a conceptual hierarchy of
16 determinants, which we have previously proposed for leptospirosis. An online database for
17 *Leptospira* MLST will be used for typing analysis.

19 **Patient and public involvement**

20 The study was developed based on the patients' feedback regarding leptospirosis disease
21 burden, its impact on their lives, and in particular, the problems faced during illness. In previous
22 studies, we specifically explored patients as well as general public views on leptospirosis disease
23 and prevention, and used this information for the design of this study. Moreover, the results of this
24 study will be disseminated on a continuous basis for the patients. We have already conducted several
25 public awareness and health worker education workshops based on our findings.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

2 ETHICS AND DISSEMINATION

3 Undifferentiated fever patients eligible for the study will be given an explanatory statement
4 of the study and written informed consent will be obtained before enrolment. Rapid diagnostic kits
5 will be used on site to assist treating physicians. qPCR diagnostic facilities will be provided for all
6 patients whenever the urgent tests are requested by treating physicians. All test results will be
7 informed to the patients and the wards. Ethical clearance for the study was obtained from the Ethic
8 Review Committees of Faculty of Medicine and Allied Sciences, Rajarata University of Sri Lanka
9 (ERC/2015/18).

10 All genomic data will be deposited in Gene Bank. Characterized serum samples will be
11 stored in -80C in the Faculty of Medicine and Allied Sciences, Rajarata University of Sri Lanka.
12 Data pertaining to this study will be available for researchers and policy makers on a reasonable
13 request address to the corresponding author. After the completion of work, data will be deposited
14 in a repository.

16 REFERENCES

- 17 1. WER: **Leptospirosis worldwide, 1999.** *Wkly Epidemiol Rec* 1999, **74**(29):237-242.
- 18 2. Costa F, Hagan JE, Calcagno J, Kane M, Torgerson P, Martinez-Silveira MS, Stein C, Abela-Ridder B, Ko AI: **Global Morbidity and Mortality of Leptospirosis: A Systematic Review.** *PLoS Negl Trop Dis* 2015, **9**(9):e0003898.
- 19 3. Taylor AJ, Paris DH, Newton PN: **A Systematic Review of the Mortality from Untreated Leptospirosis.** *PLoS Negl Trop Dis* 2015, **9**(6):e0003866.
- 20 4. Agampodi S, Peacock SJ, Thevanesam V: **The potential emergence of leptospirosis in Sri Lanka.** *Lancet Infect Dis* 2009, **9**(9):524-526.
- 21 5. Epidemiological Unit: **Selected notifiable diseases reported by Medical Officers of Health.** *Weekly Epidemiological Report* 2009, **36**(1):4.
- 22 6. Epidemiological Unit: **Selected notifiable diseases reported by Medical Officers of Health.** *Weekly Epidemiological Report* 2010, **37**(1):4.
- 23 7. Warnasekara JN, Agampodi S: **Leptospirosis in Sri Lanka.** *Sri Lankan Journal of Infectious Diseases* 2017, **7**(2).
- 24 8. Pappas G, Papadimitriou P, Siozopoulou V, Christou L, Akritidis N: **The globalization of leptospirosis: worldwide incidence trends.** *Int J Infect Dis* 2008, **12**(4):351-357.
- 25 9. Agampodi SB, Peacock SJ, Thevanesam V, Nugegoda DB, Smythe L, Thaipadungpanit J, Craig SB, Burns MA, Dohnt M, Boonsilp S *et al*: **Leptospirosis outbreak in Sri Lanka in 2008: lessons for assessing the global burden of disease.** *Am J Trop Med Hyg* 2011, **85**(3):471-478.
- 26 10. Agampodi SB, Dahanayaka NJ, Bandaranayaka AK, Perera M, Priyankara S, Weerawansa P, Matthias MA, Vinetz JM: **Regional differences of leptospirosis in Sri Lanka:**

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 1 observations from a flood-associated outbreak in 2011. *PLoS Negl Trop Dis* 2014, **8**(1):e2626.
 - 2
 - 3
 - 4 11. Myers WP, Myers AP, Cox-Singh J, Lau HC, Mokuai B, Malley R: **Micro-geographic risk factors for malarial infection.** *Malaria journal* 2009, **8**:27.
 - 5
 - 6 12. Schellenberg JA, Newell JN, Snow RW, Mung'ala V, Marsh K, Smith PG, Hayes RJ: **An analysis of the geographical distribution of severe malaria in children in Kilifi District, Kenya.** *Int J Epidemiol* 1998, **27**(2):323-329.
 - 7
 - 8
 - 9 13. Hassan AO, Amoo AOJ, Deji-Agboola AM, Adeleke MA, Muhibi MA, Hassan RO: **Microgeographical patterns of schistosomiasis and anthropometric indices of children in eko-ende south west, nigeria.** *Int J Biol Med Res* 2911, **2**(3):656-660.
 - 10
 - 11
 - 12 14. Kloos H, Gazzinelli A, Van Zuyle P: **Microgeographical patterns of schistosomiasis and water contact behavior; examples from Africa and Brazil.** *Mem Inst Oswaldo Cruz* 1998, **93 Suppl 1**:37-50.
 - 13
 - 14
 - 15 15. Baliraine FN, Afrane YA, Amenya DA, Bonizzoni M, Menge DM, Zhou G, Zhong D, Vardo-Zalik AM, Githeko AK, Yan G: **High prevalence of asymptomatic plasmodium falciparum infections in a highland area of western Kenya: a cohort study.** *J Infect Dis* 2009, **200**(1):66-74.
 - 16
 - 17
 - 18 16. Dissanayake CB, Chandrajith R: **Medical geochemistry of tropical environments.** *Earth-Science Reviews* 1999, **47**(3-4):219-258.
 - 19
 - 20
 - 21 17. Naotunna C, Agampodi SB, Agampodi TC: **Etiological agents causing leptospirosis in Sri Lanka: A review.** *Asian Pac J Trop Med* 2016, **9**(4):390-394.
 - 22
 - 23
 - 24 18. Agampodi SB, Moreno AC, Vinetz JM, Matthias MA: **Utility and limitations of direct multi-locus sequence typing on qPCR-positive blood to determine infecting Leptospira strain.** *Am J Trop Med Hyg* 2013, **88**(1):184-185.
 - 25
 - 26
 - 27 19. Agampodi SB, Miatthias MA, Moreno AC, Vinetz JM: **Utility of Quantitative PCR in Leptospirosis Diagnosis: Association of Level of Leptospiremia and Clinical Manifestations in Sri Lanka.** *Clinical Infectious Disease* 2012, **In Press**.
 - 28
 - 29
 - 30 20. Katz AR: **Quantitative polymerase chain reaction: filling the gap for early leptospirosis diagnosis.** *Clin Infect Dis* 2012, **54**(9):1256-1258.
 - 31
 - 32
 - 33 21. Nityananda K, Harvey T: **Leptospirosis in Ceylon-Epidemiological and Laboratory Studies.** *Ceylon J Med Sci* 1971, **20**(1):5-14.
 - 34
 - 35
 - 36 22. Agampodi SB, Nugegoda DB, Thevanesam V: **Determinants of leptospirosis in Sri Lanka: Study Protocol.** *BMC Infect Dis* 2010, **10**(1):332.
 - 37
 - 38
 - 39 23. Agampodi SB, Matthias MA, Moreno AC, Vinetz JM: **Utility of quantitative polymerase chain reaction in leptospirosis diagnosis: association of level of leptospiremia and clinical manifestations in Sri Lanka.** *Clin Infect Dis* 2012, **54**(9):1249-1255.
 - 40
 - 41
 - 42 24. Reller ME, Bodinayake C, Nagahawatte A, Devasiri V, Kodikara-Arachichi W, Strouse JJ, Flom JE, Dumler JS, Woods CW: **Leptospirosis as frequent cause of acute febrile illness in southern Sri Lanka.** *Emerg Infect Dis* 2011, **17**(9):1678-1684.
 - 43
 - 44
 - 45 25. Lucchesi PM, Arroyo GH, Etcheverria AI, Parma AE, Seijo AC: **Recommendations for the detection of Leptospira in urine by PCR.** *Rev Soc Bras Med Trop* 2004, **37**(2):131-134.
 - 46
 - 47
 - 48 26. Bal AE, Gravekamp C, Hartskeerl RA, De Meza-Brewster J, Korver H, Terpstra WJ: **Detection of leptospire in urine by PCR for early diagnosis of leptospirosis.** *J Clin Microbiol* 1994, **32**(8):1894-1898.
 - 49
 - 50
 - 51 27. Van Eys GJ, Gravekamp C, Gerritsen MJ, Quint W, Cornelissen MT, Schegget JT, Terpstra WJ: **Detection of leptospire in urine by polymerase chain reaction.** *J Clin Microbiol* 1989, **27**(10):2258-2262.
 - 52
 - 53
 - 54 28. World Health Organization: **Report of the second meeting of leptospirosis burden epidemiology reference group.** In. Geneva: World Health Organization 2011: 1-34.
 - 55
 - 56
 - 57 29. Wuthiekanun V, Chierakul W, Limmathurotsakul D, Smythe LD, Symonds ML, Dohnt MF, Slack AT, Limpai boon R, Suputtamongkol Y, White NJ *et al*: **Optimization of**
 - 58
 - 59
 - 60

- 1 **culture of *Leptospira* from humans with leptospirosis. *J Clin Microbiol* 2007,**
 2 **45(4):1363-1365.**
- 3 30. Wuthiekanun V, Amornchai P, Langla S, Oyuchua M, Day NP, Limmathurotsakul D:
 4 **Maintenance of leptospira species in leptospira Vanaporn Wuthiekanun agar. *J Clin***
 5 ***Microbiol* 2014, 52(12):4350-4352.**
- 6 31. Wuthiekanun V, Amornchai P, Langla S, White NJ, Day NP, Limmathurotsakul D,
 7 Peacock SJ: **Antimicrobial Disk Susceptibility Testing of *Leptospira* spp. Using**
 8 ***Leptospira* Vanaporn Wuthiekanun (LVW) Agar. *Am J Trop Med Hyg* 2015,**
 9 **93(2):241-243.**
- 10 32. Wuthiekanun V, White NJ, Amornchai P, Day NP, Limmathurotsakul D: **Quality controls**
 11 **for antimicrobial disk diffusion testing on *Leptospira* Vanaporn Wuthiekanun agar.**
 12 ***Trans R Soc Trop Med Hyg* 2016, 110(11):673-675.**
- 13 33. Picardeau M, Bulach DM, Bouchier C, Zuerner RL, Zidane N, Wilson PJ, Creno S,
 14 Kuczek ES, Bommezzadri S, Davis JC *et al*: **Genome sequence of the saprophyte**
 15 ***Leptospira biflexa* provides insights into the evolution of *Leptospira* and the**
 16 **pathogenesis of leptospirosis. *PLoS ONE* 2008, 3(2):e1607.**
- 17 34. Backstedt BT, Buyuktanir O, Lindow J, Wunder EA, Reis MG, Usmani-Brown S, Ledizet
 18 M, Ko A, Pal U: **Efficient Detection of Pathogenic *Leptospira* Using 16S Ribosomal**
 19 **RNA. *PLOS ONE* 2015, 10(6):e0128913-e0128913.**
- 20 35. Ferreira AS, Costa P, Rocha T, Amaro A, Vieira ML, Ahmed A, Thompson G, Hartskeerl
 21 RA, Inacio J: **Direct detection and differentiation of pathogenic *Leptospira* species**
 22 **using a multi-gene targeted real time PCR approach. *PLoS One* 2014, 9(11):e112312.**
- 23 36. Seemann T: **Prokka: rapid prokaryotic genome annotation. *Bioinformatics* 2014,**
 24 **30(14):2068-2069.**
- 25 37. Page AJ, Cummins CA, Hunt M, Wong VK, Reuter S, Holden MT, Fookes M, Falush D,
 26 Keane JA, Parkhill J: **Roary: rapid large-scale prokaryote pan genome analysis.**
 27 ***Bioinformatics* 2015, 31(22):3691-3693.**
- 28 38. Huerta-Cepas J, Forslund K, Coelho LP, Szklarczyk D, Jensen LJ, von Mering C, Bork P:
 29 **Fast Genome-Wide Functional Annotation through Orthology Assignment by**
 30 **eggNOG-Mapper. *Mol Biol Evol* 2017, 34(8):2115-2122.**
- 31 39. Wood DE, Salzberg SL: **Kraken: ultrafast metagenomic sequence classification using**
 32 **exact alignments. *Genome Biol* 2014, 15(3):R46.**
- 33 40. Varni V, Ruybal P, Lauthier JJ, Tomasini N, Brihuega B, Koval A, Caimi K:
 34 **Reassessment of MLST schemes for *Leptospira* spp. typing worldwide. *Infect Genet***
 35 ***Evol* 2014, 22:216-222.**
- 36 41. Ahmed N, Devi SM, Valverde Mde L, Vijayachari P, Machang'u RS, Ellis WA, Hartskeerl
 37 RA: **Multilocus sequence typing method for identification and genotypic classification**
 38 **of pathogenic *Leptospira* species. *Ann Clin Microbiol Antimicrob* 2006, 5:28.**
- 39 42. Boonsilp S, Thaipadungpanit J, Amornchai P, Wuthiekanun V, Bailey MS, Holden MT,
 40 Zhang C, Jiang X, Koizumi N, Taylor K *et al*: **A single multilocus sequence typing**
 41 **(MLST) scheme for seven pathogenic *Leptospira* species. *PLoS Negl Trop Dis* 2013,**
 42 **7(1):e1954.**

AUTHORS' CONTRIBUTIONS

JVV and SBA drafted the initial protocol. YPJNW·JMDDJ and RMISKS are responsible
 for the detailed design, field/ laboratory work analysis and interpretation of objectives 1-3, 4 and 5
 respectively. CDG, SAMK and SHS helped in design, field, hospital and laboratory work. MM

1 participated in scientific design and guided all laboratory components. All authors have read and
2 approved the manuscript.
3
4

5
6 3

8 **FUNDING**

9
10 This project is the Sri Lankan component of a multi country study funded by the NIAID of
11 the National Institutes of Health under award number U19AI115658. Funders had no role in the
12 design, execution, analyses, data interpretation, or decision to submit results.
13
14
15
16

17 8

18 **CONFLICTS OF INTERESTS**

19
20
21
22 The authors declare that they have no competing interests.
23
24

25 11

26 **WORD COUNT**

27
28
29 13 3791
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **1 FIGURES**

2
3
4 **2 Figure 1: Locations of study sites.**

5
6 **3**

7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Study sites

147x201mm (72 x 72 DPI)